

# DNA targeting half sandwich Ru(II)-*p*-cymene-N<sup>N</sup> complexes as cancer cell imaging and terminating agents: influence of regioisomers in cytotoxicity<sup>†</sup>

Ashaparna Mondal,<sup>[a]†</sup> Utsav Sen,<sup>[b]†</sup> Nilmadhab Roy,<sup>[a]</sup> Venkatesan Muthukumar,<sup>[a]</sup> Suban Kumar Sahoo <sup>[c]</sup> Bipasha Bose,<sup>\*[b]</sup> and Priyankar Paira,<sup>\*[a]</sup>

<b>Index</b>	<b>Page No</b>
<b>Fig. S1 TLC images of two isomers (8h = 11d and 8h' = 11d')</b>	<b>1</b>
<b>Fig. S2 <sup>1</sup>H NMR spectra of two separated isomers 11d and 11d'</b>	<b>2-3</b>
<b>Fig. S3-S4 DFT computed structure of the Ru(II) complexes</b>	<b>3-4</b>
<b>Table S1 Calculated parameters of the Ru(II) complexes and their regioisomers</b>	<b>4</b>
<b>Fig. S5 UV absorption spectra of the Ru(II) complexes</b>	<b>5</b>
<b>Fig. S6 Fluorescence emission spectra of the Ru(II) complexes</b>	<b>6</b>
<b>Table S2 Solubility, lipophilicity and conductivity study of the synthesized ruthenium complexes</b>	<b>7</b>
<b>Fig. S7 Comparison of cytotoxicity</b>	<b>8</b>
<b>Fig. S8 Stability Study of Ru(II) complexes by UV spectra</b>	<b>9</b>
<b>Fig. S9-S11 Stability study of Ru(II) complexes by NMR</b>	<b>10-12</b>
<b>Fig. S12 UV-vis absorption spectrum of moderately potent compound 8I7 in absence and in presence of Ct-DNA in TrisHCl buffer</b>	<b>13</b>
<b>Fig. S13 Fluorescence emission spectra (<math>\lambda_{ex}</math> = 485 nm) of Ct-DNA-EtBr complex in Tris-HCl buffer (pH 7.8, T = 25 °C) in absence and presence of compound 8I7.</b>	<b>13</b>
<b>Fig. S14 UV-Vis absorption band of in 1 mM GSH</b>	<b>14</b>
<b>Characterization of ligand and Ru(II) complexes by NMR, Mass, IR spectra and XRD</b>	<b>15-162</b>
<b>Experimental Section</b>	<b>163-184</b>
<b>References</b>	<b>185</b>






Fig. S1 TLC images of two isomers (8h = 11d and 8h' = 11d')




(Above)




(Below)

Fig. S2 <sup>1</sup>H NMR spectra of two separated isomers 11d (above) and 11d' (below)



**Fig. S3 DFT computed structure of the complexes (a) 5f (b) 11b (c) 11l (d) 11d (e) 11e (f) 11f.**



**Fig. S4 DFT computed structure of the regioisomer of the complexes (a) 5f' (b) 11b' (c) 11l' (d) 11d' (e) 11e' (f) 11f'.**

**Table S1 Calculated parameters of the complexes 5d, 5f, 11b, 11g, 11h, 11i, 11j and their regioisomers**

Complex	Parameters of isomer 1				Parameters of isomer 2			
	$E_T$ (a.u.)	$E_{LUMO}$ (eV)	$E_{HOMO}$ (eV)	$\Delta E$	$E_T$ (a.u.)	$E_{LUMO}$ (eV)	$E_{HOMO}$ (eV)	$\Delta E$
<b>5d</b>	- 4477.66866821	- 0.16023	- 0.38047	0.22024	- 4477.66768295	-0.16091	- 0.38127	0.22036
<b>5f</b>	- 4345.13889634	- 0.16673	- 0.38417	0.21744	- 4345.13700718	-0.16944	- 0.38556	0.21612
<b>11b</b>	- 2182.96620205	- 0.16130	- 0.37249	0.21119	- 2182.96603210	-0.16110	- 0.37237	0.21127
<b>11l</b>	- 4294.27505340	- 0.16094	- 0.37221	0.21127	- 4294.27483267	-0.16078	- 0.37149	0.21071
<b>11d</b>	- 2060.33098734	- 0.16288	- 0.37400	0.21112	- 2060.33011619	-0.16344	- 0.37499	0.21155
<b>11e</b>	- 1837.85515419	- 0.15427	- 0.36065	0.20638	- 1837.85717876	-0.15235	- 0.35830	0.20595
<b>11f</b>	- 1927.80137214	- 0.16829	- 0.37756	0.20927	- 1927.79967194	-0.17050	- 0.37924	0.20874

## UV spectra of synthesized compounds







Fig. S5 UV absorption bands of (a) $(\eta^6-p\text{-cymene})\text{Ru}(\text{II})\text{chlorido-2-(6-bromopyridinyl) BIZ, BTZ complexes}$ ; (b) $(\eta^6-p\text{-cymene})\text{Ru}(\text{II})\text{chlorido-2-(6-arylpyridinyl) BIZ, BTZ complexes}$ ; (c) $(\eta^6-p\text{-cymene})\text{Ru}(\text{II})\text{chlorido-2-quinolinyl BIZ, BTZ and BOZ complexes}$





Fig. S6 Fluorescence emission bands of (a) $(\eta^6-p\text{-cymene})\text{Ru}(\text{II})\text{chlorido-2-(6-bromopyridinyl) BIZ, BTZ complexes}$ ; (b) $(\eta^6-p\text{-cymene})\text{Ru}(\text{II})\text{chlorido-2-(6-arylpyridinyl) BIZ, BTZ complexes}$  (c) $(\eta^6-p\text{-cymene})\text{Ru}(\text{II})\text{chlorido-2-quinolinyl BIZ, BTZ \& BOZ complexes}$


**Table S2** Solubility, lipophilicity and conductivity study of the synthesized ruthenium complexes

Samples	Solubility (M) <sup>a</sup>	Log P <sup>b</sup>	$\Lambda_M^c$ (S cm <sup>2</sup> M <sup>-1</sup> )	
			DMSO (pure)	DMSO (10%)
5a	0.060	0.69±0.05	28	32
5b	0.063	0.86±0.07	29	30
5b'	0.061	0.90±0.06	28	30
5c	0.068	1.4±0.07	30	35
5c'	0.065	1.29±0.05	31	34
5d	0.067	1.34±0.07	29	35
5d'	0.067	1.32±0.03	30	36
5e	0.071	0.66±0.09	31	37
5e'	0.078	0.68±0.07	32	38
5f	0.072	1.14±0.07	29	33
5f'	0.072	1.07±0.05	30	34
5g (less soluble)	0.024	0.79±0.07	32	35
5h	0.076	0.92±0.04	33	38
8g1	0.071	0.93±0.08	34	39
8g2	0.072	0.95±0.07	35	40
8g3	0.074	0.96±0.05	33	39
8l1	0.070	0.97±0.09	33	38
8l2	0.075	0.99±0.08	34	40
8l3		1.17±0.06	32	35
	0.076			
8l4	0.069	1.19±0.08	35	39
8l5	0.064	1.21±0.07	35	39
8l6	0.070	1.23±0.05	32	38
8l7	0.072	1.19±0.07	34	37
8l8	0.071	1.20±0.1	32	39
8l9	0.075	0.99±0.07	32	39
11a	0.069	0.92±0.08	30	37
11b	0.071	1.3±0.1	31	36
11b'	0.071	1.4±0.07	29	38
11d	0.082	1.45±0.07	28	34
11d'	0.082	1.34±0.08	29	36
11e	0.071	1.2±0.07	32	38
11e'	0.071	1.1±0.17	31	37
11f	0.069	0.97±0.1	34	36
11f'	0.069	0.92±0.08	35	40
11h	0.068	0.97±0.07	30	35
11i	0.064	1.17±0.1	32	37
11j	0.066	1.30±0.04	34	38
11k	0.067	1.35±0.08	29	35
11k'	0.062	1.34±0.09	30	40
11l	0.074	1.07±0.06	32	38
11l'	0.074	1.04±0.09	33	37
11m	0.069	0.97±0.17	34	38
11n	0.071	0.99±0.04	34	39

<sup>a</sup>DMSO-10% DMEM medium (1:99 v/v, comparable to cell media), <sup>b</sup>n-Octanol/Water Partition Coefficients, <sup>c</sup>Molar Conductance



**Fig. S7 Comparison of cytotoxicity for complexes 5a-h in (a) HeLa (b) CaCo-2 and (g) HEK-293 cell line; complexes 8g1-8i9 in (c) HeLa (d) CaCo-2 and (h) HEK-293 cell line; complexes 11a-n in (e) HeLa (f) CaCo-2 and (i) HEK-293 cell line**



(Left)

(Right)

Fig. S8. Left: UV-Vis absorption band of complexes (a) 5h and (b) 11j ( $c = 2 \times 10^{-5}$  M) in 5% DMSO in phosphate buffer, pH = 7.4 with time interval. Right: UV-Vis absorption band of complexes (a) 5h and (b) 11j ( $c = 2 \times 10^{-5}$  M) in (Water pH 7.4)








Fig. S9 NMR spectra of compound 5h in DMSO-*d*<sub>6</sub> recorded at 0<sup>th</sup>, 6<sup>th</sup> and 24<sup>th</sup> h after dissolving in solvent




Fig. S10 NMR spectra of compound 11j in DMSO-*d*<sub>6</sub> recorded at 0<sup>th</sup>, 6<sup>th</sup> and 24<sup>th</sup> h after dissolving in solvent




Fig. S11 NMR spectra of compound 11j in D<sub>2</sub>O recorded at 0<sup>th</sup>, 6<sup>th</sup> and 24<sup>th</sup> hour after dissolving in solvent (PH 7.4)







Fig. S12 UV-vis absorption spectrum of moderately potent compound 817 in absence and in presence of 10, 15, 20, ..... 90, 95, 100  $\mu\text{M}$  of ct-DNA in TrisHCl buffer (pH 7.4,  $T = 25\text{ }^\circ\text{C}$ ). Change in absorbance with increasing DNA concentration happened in the direction of arrow. Inset: plot of  $[\text{DNA}]/(\epsilon_a - \epsilon_f)$  vs  $[\text{DNA}]$  for 817





Fig. S13 Fluorescence emission spectra ( $\lambda_{\text{ex}} = 485\text{ nm}$ ) of Ct-DNA-EtBr complex in Tris-HCl buffer (pH 7.4,  $T = 25\text{ }^\circ\text{C}$ ) in absence and presence of 5, 10, 15, 20, ....80, 85  $\mu\text{M}$  of compound 817. Inset: plot of  $I_0/I$  vs.  $[Q]$ . and Plot of  $\log [(I_0 - I)/I]$  vs.  $\log [Q]$  for compound 817





Fig. S14 UV-Vis absorption band of complexes (a) 5h and (b) 11j ( $c = 2 \times 10^{-5}$  M) in 1 mM GSH




# Pyridine Series

## <sup>1</sup>H NMR of ligand 3a




# <sup>1</sup>H and <sup>13</sup>C NMR of complex 5a-h


5a



5a




5b



5b

Signature SIF VIT VELLORE  
RBIZ-15


156.41  
149.63  
147.50  
141.92  
139.57  
134.77  
130.74  
129.69  
125.33  
121.49  
119.93  
117.56  
104.65  
101.22  
80.66  
79.77  
79.44  
79.11  
40.56  
40.35  
40.14  
39.94  
39.73  
39.52  
39.31  
31.16  
22.70  
21.78  
19.13



p-cymene aromatic  
carbons

p-cymene aliphatic  
carbons

Ligand carbons




Current Data Parameters  
NAME 02-01-17  
EXPNO 6  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20170102  
Time 20.29 h  
INSTRUM spect  
PROBHD z109618\_0505 (zggg30)  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
RG 1024  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
DW 20.800 usec  
DE 6.50 usec  
TE 300.6 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TDO 1  
SFO1 100.6550186 MHz  
NUC1 13c  
P1 9.80 usec  
PIW1 58.00000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
CPCPRG2 waltz16  
PCPD2 90.00 usec  
PIW2 14.00000000 W  
PIW12 0.35097000 W  
PIW13 0.17654000 W


F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40




5b'



5b'




5c




5c

Signature SIF VIT VELLORE  
5C




5c'







5c'




5d



5d




5d'




5d'

Signature SIF VIT VELLORE  
5D







5e




5e'



5f



Signature SIF VIT VELLORE  
RBIZ (5F)



```

Current Data Parameters
NAME      Dr.PP180120
EXPNO    51
PROCNO    1



F2 - Acquisition Parameters
Date_    20200118
Time     23.25 h
INSTRUM  spect
PROBHD   5106418_0505 (
PULPROG  zgpg30
TD        65536
SOLVENT  DMSO
NS        2000
DS        4
SWH       24038.461 Hz
FIDRES    0.733596 Hz
AQ        1.3631488 sec
RG        199.6
RW        20.800 usec
DE        6.50 usec
TE        298.2 K
D1        2.00000000 sec
D11       0.03000000 sec
TD0       1
SFO1      100.625181 MHz
NUC1      13C
P1        9.80 usec
PLM1      58.00000000 W
SFO2      400.2590010 MHz
NUC2      1H
CPDPRG12 waltz16
PCPD2     90.00 usec
PLM2      16.00000000 W
PLM12     0.38716000 W
PLM13     0.19474000 W

F2 - Processing parameters
SI        32768
SF        100.6449542 MHz
WDW       EM
SSB       0
LB        1.00 Hz
GB        0
PC        1.40
    
```

5f'

Signature SIF VIT VELLORE  
RBIZ-19

8.503  
8.401  
8.384  
8.203  
8.180  
8.153  
7.760  
7.734  
7.716  
7.576  
7.553  
5.884  
5.869  
5.828  
5.814  
5.793  
5.779  
5.694  
5.679  
2.544  
2.385  
1.696  
0.891  
0.875  
0.858  
0.824



Current Data Parameters


NAME	04-01-17
EXPNO	7
PROCNO	1

F2 - Acquisition Parameters

Date_	20170205
Time	10.59 h
INSTRUM	spoct
PROBHD	Z108618_0505 (
PULPROG	zg30
TD	65536
SOLVENT	CDCl3
NS	64
DS	2
SWH	8012.820 Hz
FIDRES	0.244552 Hz
AQ	4.0894465 sec
RG	199.6
DW	62.400 usec
DE	6.50 usec
TE	298.8 K
D1	1.00000000 sec
TDO	1
SFO1	400.2604716 MHz
NUC1	1H
P1	14.25 usec
PLW1	14.00000000 W


F2 - Processing parameters

SI	65536
SF	400.2580098 MHz
WDW	EM
SSB	0
LB	0.30 Hz
GB	0
PC	1.00







5f'




# <sup>1</sup>H NMR of ligand 3g




5g



5g





5h






5h







**ESI-MS spectra of complex 5a**




**ESI-MS spectra of complex 5c**




## ESI-MS spectra of complex 5d




## ESI-MS spectra of complex 5e



## ESI-MS spectra of complex 5f




## ESI-MS spectra of complex 5g




## ESI-MS spectra of complex 5h



# Suzuki Series




<sup>1</sup>H NMR of ligand 7g1




<sup>13</sup>C NMR of ligand 7g1

# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 319.08[M+H]<sup>+</sup>





ESI-MS spectra of complex 7g1

Signature SIF VIT VELLORE  
RPBTZS-3B



**<sup>1</sup>H NMR of ligand 8g1**

Signature SIF VIT VELLORE  
3B




p-cymene aliphatic carbons

p-cymene aromatic carbons

Ligand carbons

Methoxy carbons




Current Data Parameters  
NAME Desktop  
EXPNO 49  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20200118  
Time 21.22 h  
INSTRUM spect  
PROBHD Z108618\_0505  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 2000  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
DW 20.900 usec  
DE 6.50 usec  
TE 298.3 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TD0 1  
SFO1 100.6550186 MHz  
NUC1 13C  
F1 9.80 usec  
PLW1 58.0000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
PLW2 16.0000000 W  
PLW12 0.38716000 W  
PLW13 0.19474000 W


F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

<sup>13</sup>C NMR of ligand 8g1




### <sup>31</sup>P and <sup>19</sup>F NMR of complex 8g1


## TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 589.06 [M<sup>+</sup>]








## ESI-MS spectra of complex 8g1



<sup>1</sup>H NMR of ligand 7g2




<sup>13</sup>C NMR of ligand 7g2

# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 317.09[M+H]<sup>+</sup>




## ESI-MS spectra of complex 7g2




## <sup>31</sup>P and <sup>19</sup>F NMR of complex 8g2


# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 587.05 [M<sup>+</sup>]



ESI-MS spectra of complex 8g2




<sup>1</sup>H NMR of ligand 7g3



<sup>13</sup>C NMR of ligand 7g3


TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 331.08 [M+H]<sup>+</sup>






## ESI-MS spectra of complex 7g3

Signature SIF VIT VELLORE  
RPBTZS-5B




<sup>1</sup>H NMR of ligand 8g3




### <sup>31</sup>P and <sup>19</sup>F NMR of complex 8g3


## TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 601.06[M<sup>+</sup>]



### ESI-MS spectra of complex 8g3




<sup>1</sup>H NMR of ligand 711




<sup>13</sup>C NMR of ligand 711

TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 323.03[M+H]<sup>+</sup>




## ESI-MS spectra of complex 711






### <sup>1</sup>H NMR of ligand 811




# $^{31}\text{P}$ and $^{19}\text{F}$ NMR of complex 8I1


## TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 593.02[M<sup>+</sup>]



## ESI-MS spectra of complex 8I1




<sup>1</sup>H NMR of ligand 712




<sup>13</sup>C NMR of ligand 712


TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 351.03[M+H]<sup>+</sup>



**ESI-MS spectra of complex 712**




### <sup>1</sup>H NMR of ligand 812






# $^{31}\text{P}$ and $^{19}\text{F}$ NMR of complex 8I2

## TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 621.01 [M<sup>+</sup>]




## ESI-MS spectra of complex 8I2






<sup>1</sup>H NMR of ligand 713



<sup>13</sup>C NMR of ligand 713


# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 365.04[M+H]<sup>+</sup>



ESI-MS spectra of complex 713

Signature SIF VIT VELLORE  
RPBTZS-5A

8.238  
8.229  
8.224  
8.033  
8.011  
7.990  
7.964  
7.808  
7.800  
7.794  
7.785  
7.673  
7.655  
7.200  
5.585  
5.570  
5.456  
5.441  
5.415  
5.401  
2.697  
2.367  
2.350  
2.333  
2.110  
1.544  
0.885  
0.869  
0.621  
0.604




Current Data Parameters  
NAME RPBTZS NMR RAW DATA  
EXPNO 103  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180301  
Time 20.22 h  
INSTRUM spect  
PROBHD z108618\_0505 (   
PULPROG zg30  
TD 65536  
SOLVENT cdcl3  
NS 64  
DS 2  
SWH 8012.820 Hz  
FIDRES 0.244532 Hz  
AQ 4.0894465 sec  
RG 199.6  
DW 62.400 usec  
DE 6.50 usec  
TE 298.0 K  
D1 1.00000000 sec  
TD0 1  
SF01 400.2604716 MHz  
NUC1 1H  
F1 14.25 usec  
FWD1 14.00000000 w


F2 - Processing parameters  
SI 65536  
SF 400.2580335 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
FC 1.00

<sup>1</sup>H NMR of ligand 8I3




### $^{31}\text{P}$ and $^{19}\text{F}$ NMR of complex 8I3


# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 635.03[M<sup>+</sup>]



LC-MS spectra of complex 8I3




<sup>1</sup>H NMR of ligand 714





<sup>13</sup>C NMR of ligand 714




# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 356.99[M+H]<sup>+</sup>




ESI-MS spectra of ligand 714




# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 626.98 [M<sup>+</sup>]




## ESI-MS spectra of complex 8I4



<sup>1</sup>H NMR of ligand 715




<sup>13</sup>C NMR of ligand 715




**$^{19}\text{F}$  NMR of ligand 715**

**TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR  
 $341.02[\text{M}+\text{H}]^+$**




**ESI-MS spectra of ligand 715**




**<sup>31</sup>P and <sup>19</sup>F NMR of complex 815**




# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 611.01 [M<sup>+</sup>]




## ESI-MS spectra of complex 8I5



<sup>1</sup>H NMR of ligand 716




<sup>13</sup>C NMR of ligand 716




### $^{19}\text{F}$ NMR of ligand 716

## TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 391.02[M+H]<sup>+</sup>




### ESI-MS spectra of ligand 716

Signature SIF VIT VELLORE  
RPBTZS-8A




<sup>1</sup>H NMR of ligand 8I6




**$^{31}\text{P}$  and  $^{19}\text{F}$  NMR of complex 816**

# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 661.01 [M<sup>+</sup>]




**ESI-MS spectra of complex 8I6**






<sup>1</sup>H NMR of ligand 717




<sup>13</sup>C NMR of ligand 717

# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 373.05 [M+H]<sup>+</sup>




ESI-MS spectra of ligand 717

Signature SIF VIT VELLORE  
RPBTZS-9A




Current Data Parameters  
 NAME RPBTZS NMR RAW DATA  
 EXPNO 46  
 PROCNO 1  
 F2 - Acquisition Parameters  
 Date\_ 20181027  
 Time 6.42 h  
 INSTRUM spect  
 PROBRD z108618\_0505 ( )  
 PULPROG zg30  
 TD 65536  
 SOLVENT DMSO  
 NS 16  
 DS 2  
 SWH 8012.820 Hz  
 FIDRES 0.244532 Hz  
 AQ 4.0894465 sec  
 RG 58.47  
 DW 62.400 usec  
 DE 6.50 usec  
 TE 297.9 K  
 D1 1.00000000 sec  
 TDD 1  
 SFO1 400.2604716 MHz  
 NUC1 1H  
 F1 14.27 usec  
 PLW1 15.00000000 W  
 F2 - Processing parameters  
 SI 65536  
 SF 400.2580031 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

**<sup>1</sup>H NMR of ligand 8I7**




### $^{31}\text{P}$ and $^{19}\text{F}$ NMR of complex 817


# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 643.03[M<sup>+</sup>]



ESI-MS spectra of complex 8I7




$^1\text{H}$  NMR of ligand 718



$^{13}\text{C}$  NMR of ligand 718




# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 379.01 [M+H]<sup>+</sup>




ESI-MS spectra of ligand 718

Signature SIF VIT VELLORE  
RPBTZS-112A



<sup>1</sup>H NMR of ligand 818

Signature SIF VIT VELLORE  
RPBTZS12A




```

Current Data Parameters
NAME      Dr.PP180120
EXPNO    47
PROCNO   1

F2 - Acquisition Parameters
Date_     20200118
Time      19.18 h
INSTRUM   spect
PROBHD    Z108618_0505 (
PULPROG   zgpg30
TD         65536
SOLVENT   DMSO
NS         2000
DS         4
SWH        24038.461 Hz
FIDRES     0.732596 Hz
AQ         1.3631888 sec
RG         199.6
DW         20.800 usec
DE         6.50 usec
TE         297.8 K
D1         2.00000000 sec
D11        0.03000000 sec
TDO        1
SFO1       100.6250186 MHz
NUC1       13C
P1         9.80 usec
PIW1       58.00000000 W
SFO2       400.2596010 MHz
NUC2       1H
CPDPRG2   waltz16
PCPD2     90.00 usec
PIW2       16.00000000 W
PIW12     0.38716000 W
PIW13     0.19474000 W


F2 - Processing parameters
SI         32768
SF         100.6449542 MHz
KW         RM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40
  
```

<sup>13</sup>C NMR of ligand 818




### $^{31}\text{P}$ and $^{19}\text{F}$ NMR of complex 818


# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 648.99[M<sup>+</sup>]



## ESI-MS spectra of complex 8I8




<sup>1</sup>H NMR of ligand 719



<sup>13</sup>C NMR of ligand 719




# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 364.03 [M+H]<sup>+</sup>




## ESI-MS spectra of ligand 719

Signature SIF VIT VELLORE  
RPBTZS-13A






**<sup>1</sup>H NMR of ligand 819**




**$^{31}\text{P}$  and  $^{19}\text{F}$  NMR of complex 819**

# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 633.01 [M<sup>+</sup>]




## ESI-MS spectra of complex 8I9

# Quinoline Series



<sup>1</sup>H NMR of ligand 10a




**<sup>1</sup>H NMR of ligand 10h**



# $^1\text{H}$ and $^{13}\text{C}$ NMR of complex 11a-11n


11a



11a


Signature SIF VIT VELLORE  
RBIZ(11a)

151.05  
148.96  
142.47  
141.81  
138.09  
133.61  
130.47  
130.21  
129.80  
129.69  
129.28  
126.57  
125.56  
119.22  
118.35  
115.14  
106.85  
100.57  
86.83  
85.97  
85.67  
84.15  
40.54  
40.34  
40.13  
39.92  
39.71  
39.50  
39.29  
30.75  
22.08  
18.95



p-cymene aromatic carbons


Ligand carbons




Current Data Parameters  
NAME Desktop  
EXPNO 24  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20191216  
Time 14.27 h  
INSTRUM spect  
PROBHD Z106618\_0509 ( )  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 2000  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
DW 20.800 usec  
DE 6.50 usec  
TE 296.9 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TDO 1  
SFO1 100.6250186 MHz  
NUC1 13C  
P1 9.80 usec  
P1W1 58.00000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
PCPDPRG12 wait=16  
PCPD2 90.00 usec  
P1W2 16.00000000 W  
P1W12 0.38716000 W  
P1W13 0.19474000 W

F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40






11j



11j


Signature SIF VIT VELLORE  
11C



p-cymene aliphatic carbons

p-cymene aromatic carbons

Ligand carbons




Current Data Parameters  
NAME Dr.PP100120  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20200110  
Time 2.08 h  
INSTRUM spect  
PROBRD E108618\_0505 ( )  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 2000  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
SW 20.800 usec  
DE 6.50 usec  
TE 297.7 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TD0 1  
SFO1 100.6550186 MHz  
NUC1 13C  
P1 9.80 usec  
P1M1 58.0000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
P1M2 16.0000000 W  
P1M12 0.38716000 W  
P1M13 0.19474000 W


F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40



11b



11b





11b'

Signature SIF VIT VELLORE  
RBI7-4 (M)




8.710  
8.700  
8.688  
8.678  
8.464  
8.443  
8.049  
8.046  
7.942  
7.924  
7.715  
7.696  
7.662  
7.657  
7.641  
7.441  
7.412  
7.390  
7.376  
7.200  
5.737  
5.720  
5.699  
5.421  
5.407  
2.290  
2.213  
1.700  
0.805  
0.788  
0.753  
0.736



Current Data Parameters  
NAME Desktop  
EXPNO 11  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20161209  
Time 18.20 h  
INSTRUM spect  
PROBHD Z108618\_0505 ( )  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 16  
DS 2  
SWH 8012.820 Hz  
FIDRES 0.244532 Hz  
AQ 4.0894465 sec  
RG 156.91  
DW 62.400 usec  
DE 6.50 usec  
TE 298.4 K  
D1 1.00000000 sec  
TDO 1  
SFO1 400.2604716 MHz  
NUC1 1H  
P1 14.25 usec  
PLM1 14.00000000 W

F2 - Processing parameters  
SI 65536  
SF 400.2580337 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00




15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2 ppm

1.02  
1.05  
2.44  
3.10  
2.38  
3.30  
1.44  
3.10  
0.68  
3.28  
3.15

11b'

Signature SIF VIT VELLORE  
11d





11k

Signature SIF VIT VELLORE  
RBIZ-5



9.238 9.218 8.417 8.396 7.890 7.870 7.700 7.671 7.651 7.635 7.408 7.374 7.351 7.334 7.317 7.201 5.725 5.619


2.270 2.214 0.784 0.777 0.734 0.727



Current Data Parameters  
NAME Desktop  
EXPNO 13  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20170209  
Time 8.17 h  
INSTRUM spect  
PROBHD Z106618\_0505 ( )  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 16  
DS 2  
SWH 8012.820 Hz  
FIDRES 0.244532 Hz  
AQ 4.0894465 sec  
RC 143.73  
DW 62.400 usec  
DE 6.50 usec  
TE 298.5 K  
D1 1.00000000 sec  
TDO 1  
SFO1 400.2604716 MHz  
NUC1 1H  
P1 14.25 usec  
PLW1 14.00000000 W


F2 - Processing parameters  
SI 65536  
SF 400.2580340 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00





Signature SIF VIT VELLORE  
11k


162.39  
159.93  
152.31  
148.97  
148.36  
141.87  
139.21  
133.67  
129.90  
129.81  
129.71  
129.36  
129.28  
122.60  
119.26  
116.91  
106.86  
100.58  
86.83  
85.97  
85.65  
84.06  
83.79  
40.54  
40.33  
40.12  
39.91  
39.70  
39.49  
39.29  
30.44  
22.15  
21.95  
18.33



p-cymene aromatic carbons

p-cymene aliphatic carbons

Ligand carbons



```

Current Data Parameters
NAME      Desktop
EXPNO    20
PROCNO   1


F2 - Acquisition Parameters
Date_    20200216
Time     4.08 h
INSTRUM  spect
PROBHD   z108618_0305_1
PULPROG  zgpg30
TD        65536
SOLVENT  DMSO
NS        2000
DS        4
SWH       24038.461 Hz
FIDRES    0.733596 Hz
AQ         1.3631488 sec
RG         199.6
DW         20.800 usec
DE         6.50 usec
TE         297.8 K
D1         2.00000000 sec
D11        0.03000000 sec
TDO        1
SFO1      100.625010 MHz
NUC1       13C
P1         9.80 usec
PLW1      58.00000000 W
SFO2      400.2596010 MHz
NUC2       1H
CPDPRG2   waltz16
PCPD2     90.00 usec
PLW2      16.00000000 W
PLW12     0.38716000 W
PLW13     0.19474000 W

F2 - Processing parameters
SI         32768
SF         100.625010 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40
    
```

11k'



Signature SIF VIT VELLORE  
RBIZ-5



11k'

Signature SIF VIT VELLORE  
11k


162.55  
160.04  
152.47  
149.05  
148.44  
141.95  
139.29  
133.75  
129.98  
129.89  
129.79  
129.44  
129.35  
122.37  
119.34  
116.82  
106.94  
100.66  
86.90  
86.05  
85.73  
84.14  
40.62  
40.41  
40.20  
39.99  
39.78  
39.57  
39.36  
30.52  
22.23  
21.65  
18.41



Current Data Parameters  
NAME Dr.PP160220  
EXPNO 21  
PROCNO 2

F2 - Acquisition Parameters  
Date\_ 20200216  
Time 4.08 h  
INSTRUM spect  
PROBHD z108618\_0505 (   
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 2000  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
DW 20.800 usec  
DE 6.50 usec  
TE 297.8 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SFO1 100.6550186 MHz  
NUC1 13c  
P1 9.80 usec  
PLW1 58.00000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
PLW2 16.00000000 W  
PLW12 0.38716000 W  
PLW13 0.19474000 W

F2 - Processing parameters  
SI 32768  
SF 100.6449464 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40



p-cymene aliphatic  
carbons

p-cymene aromatic  
carbons

Ligands carbons

C-14,C-11,C-12  
C-15,C-9

C-c,C-d,C-e,C-f

C-i,C-j


C-8  
C-2  
C-16  
C-7  
C-5  
C-6  
C-10  
C-13  
C-4  
C-3  
C-1

C-b

C-g



C-h

C-a



Signature SIF VIT VELLORE  
RBIZ-7 (A)

8.795  
8.774  
8.404  
8.382  
8.263  
8.242  
7.939  
7.875  
7.853  
7.832  
7.813  
7.633  
7.615  
7.597  
7.512  
7.490  
7.328  
7.308  
7.201  
5.657  
5.610  
5.595  
5.521  
5.507  
2.302  
2.258  
2.239  
2.220  
2.208  
1.589  
0.730  
0.721  
0.713  
0.704



Current Data Parameters  
NAME A  
EXPNO 14  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20170124  
Time 1.44 h  
INSTRUM spect  
PROBHD z108618\_0505 |  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 64  
DS 2  
SWH 8012.820 Hz  
FIDRES 0.244532 Hz  
AQ 4.0894465 sec  
RG 199.6  
DW 62.400 usec  
DE 6.50 usec  
TE 297.6 K  
D1 1.00000000 sec  
TDO 1  
SFO1 400.2604716 MHz  
NUC1 1H  
P1 14.25 usec  
PEW1 14.00000000 W

F2 - Processing parameters  
SI 65536  
SF 400.2580337 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00

p-cymene aromatic protons

Methyl gr.CH<sub>3</sub> protons

H-a Isopropyl gr.CH<sub>3</sub> protons  
H-i,H-j

p-cymene aromatic protons

H-c,H-d,H-e,H-f


H-h

15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2 ppm

1.00  
1.22  
1.22  
1.13  
2.24  
1.39  
1.05  
1.39  
2.07  
1.03  
1.04  
3.20  
1.41  
6.05

Signature SIF VIT VELLORE  
11L


163.89  
148.98  
143.92  
141.90  
141.75  
136.23  
133.61  
130.25  
129.79  
129.66  
129.33  
128.34  
120.13  
119.76  
116.07  
113.93  
106.79  
100.51  
86.83  
85.96  
84.80  
83.52  
40.52  
40.31  
40.10  
39.90  
39.69  
39.48  
39.27  
30.70  
22.11



p-cymene aliphatic  
carbons

p-cymene aromatic  
carbons

Ligand carbons




Current Data Parameters  
NAME Desktop  
EXPNO 14  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20200215  
Time 22.06 h  
INSTRUM spect  
PROBHD Z108610\_0505 ( )  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 2000  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
DW 20.800 usec  
DE 6.50 usec  
TE 297.6 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TDO 1  
SFO1 100.6550186 MHz  
NUC1 13C  
F1 9.80 usec  
P1W1 58.00000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
PCPD2 waitz16  
PCPD2 90.00 usec  
P1W2 16.00000000 W  
P1W12 0.38716000 W  
P1W13 0.19474000 W


F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

Signature SIF VIT VELLORE  
RBIZ-7 (B)





Signature SIF VIT VELLORE  
11L




11d






Signature SIF VIT VELLORE  
11b




11d'



11d'

Signature SIF VIT VELLORE  
11b




Current Data Parameters  
NAME Desktop  
EXPNO 28  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20200216  
Time 12.12 h  
INSTRUM spect  
PROBHD Z10618\_0505 (1  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 2000  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
DW 20.800 usec  
DE 6.50 usec  
TE 298.5 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TDO 1  
SFO1 100.6550186 MHz  
NUC1 13C  
P1 9.80 usec  
PLW1 58.00000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
CPDPRG[2] waltz16  
PCPD2 90.00 usec  
PLW2 16.00000000 W  
PLW12 0.38716000 W  
PLW13 0.19474000 W

F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40


11e

Signature SIF VIT VELLORE  
RBIZ-9(A)



11e


Signature SIF VIT VELLORE  
RBIZ



Current Data Parameters  
NAME Desktop  
EXNO 10  
PROCNO 1

F2 - Acquisition Parameters  
Date 20200110  
Time 12.20 h  
INSTRUM spect  
PROBHD Z108618\_0505 ( )  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 512  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
DW 20.800 usec  
DE 6.50 usec  
TE 297.7 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TDO 1  
SFO1 100.6550186 MHz  
NUC1 13C  
P1 9.80 usec  
PLW1 58.00000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
CPCPRG12 waltz16  
PCPD2 90.00 usec  
PLW2 16.00000000 W  
PLW12 0.38716000 W  
PLW13 0.19474000 W


F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WCM EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40



11e'




Signature SIF VIT VELLORE  
RBI7-9(B)




11e'

Signature SIF VIT VELLORE  
RBIZQ(11D)




Signature SIF VIT VELLORE  
RBI7-10(A)



Signature SIF VIT VELLORE  
11f




164.89  
154.33  
148.98  
144.28  
141.63  
136.91  
133.40  
129.77  
129.65  
129.49  
129.28  
126.55  
122.78  
119.65  
117.55  
113.61  
106.79  
100.65  
86.82  
85.96  
85.74  
84.41  
40.52  
40.31  
40.10  
39.89  
39.68  
39.48  
39.27  
30.74  
22.22  
21.46  
18.81



p-cymene aromatic  
carbons

p-cymene aliphatic  
carbons

Ligand carbons




Current Data Parameters  
NAME Desktop  
EXPNO 18  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20200216  
Time 2.07 h  
INSTRUM spect  
PROBHD z108618\_0505 (  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 2000  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
DW 20.800 usec  
DE 6.50 usec  
TE 297.8 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SFO1 100.6550186 MHz  
NUC1 13C  
P1 9.80 usec  
PLW1 58.00000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
PLW2 16.00000000 W  
PLW12 0.38716000 W  
PLW13 0.19474000 W

F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

11f'

Signature SIF VIT VELLORE  
RBI7-10(B)



Current Data Parameters

NAME	B
EXPNO	9
PROCNO	1

F2 - Acquisition Parameters

Date_	20170119
Time	2.49 h
INSTRUM	spect
PROBHD	Z108618_0505 (
FULPROG	zg30
TD	65536
SOLVENT	CDCl3
NS	64
DS	2
SWH	8012.820 Hz
FIDRES	0.244532 Hz
AQ	4.0894465 sec
RG	199.6
DW	62.400 usec
DE	6.50 usec
TE	297.6 K
D1	1.00000000 sec
TDO	1
SFO1	400.2604716 MHz
NUC1	1H
F1	14.25 usec
PLW1	14.00000000 W

F2 - Processing parameters:


SI	65536
SF	400.2580337 MHz
WDW	EM
SSB	0
LB	0.30 Hz
GB	0
PC	1.00



Signature SIF VIT VELLORE  
11f




165.01  
154.34  
149.08  
144.37  
141.72  
138.77  
133.50  
129.87  
129.75  
129.59  
129.38  
126.65  
122.97  
119.75  
117.64  
113.71  
106.79  
100.65  
86.92  
86.06  
85.84  
84.51  
40.62  
40.41  
40.20  
39.99  
39.78  
39.57  
39.36  
30.84  
22.32  
21.56  
18.91



Current Data Parameters  
NAME Desktop  
EXPNO 19  
PROCNO 2

F2 - Acquisition Parameters  
Date\_ 20200216  
Time 2.07 h  
INSTRUM spect  
PROBHD z108618\_0505 ( )  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 2000  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
DW 20.800 usec  
DE 6.50 usec  
TE 297.8 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SFO1 100.6550186 MHz  
NUC1 13C  
P1 9.80 usec  
PLW1 58.00000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
PLW2 16.00000000 W  
PLW12 0.38716000 W  
PLW13 0.19474000 W

F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40



11h




Signature SIF VIT VELLORE  
11J



9.002  
8.981  
8.826  
8.804  
8.718  
8.698  
8.606  
8.584  
8.347  
8.333  
8.216  
8.197  
8.177  
8.031  
8.012  
7.994  
7.940  
7.918  
6.329  
6.303  
6.288  
6.090  
6.075  
3.495  
2.854  
2.836  
2.820  
2.803  
2.786  
2.500  
2.275  
0.822  
0.805  
0.749  
0.732

9.002  
8.981  
8.826  
8.804  
8.718  
8.698  
8.606  
8.584


8.347  
8.333  
8.216  
8.197  
8.177  
8.031  
8.012  
7.994  
7.940  
7.918



Current Data Parameters  
NAME Dr.PP161219  
EXPNO 21  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20191216  
Time 10.33 h  
INSTRUM spect  
PROBHD z108618\_0505 ( )  
PULPROG zg30  
TD 65536  
SOLVENT DMSO  
NS 64  
DS 2  
SWH 8012.820 Hz  
FIDRES 0.244532 Hz  
AQ 4.0894465 sec  
RG 88.69  
DW 62.400 usec  
DE 6.50 usec  
TE 297.0 K  
D1 1.00000000 sec  
TD0 1  
SFO1 400.2604716 MHz  
NUC1 1H  
F1 14.00 usec  
PLW1 16.00000000 W

F2 - Processing parameters  
SI 65536  
SF 400.2580035 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00




11h

Signature SIF VIT VELLORE  
11J



11m


Signature SIF VIT VELLORE  
11K



11m

Signature SIF VIT VELLORE  
11m


161.17  
151.24  
148.94  
145.92  
141.71  
133.58  
129.77  
129.63  
129.35  
128.60  
127.45  
123.63  
122.79  
119.31  
117.82  
116.92  
106.91  
100.59  
86.82  
85.96  
84.89  
83.77  
40.49  
40.28  
40.07  
39.87  
39.66  
39.45  
39.24  
30.65  
22.11  
21.93  
18.92



*p*-cymene aliphatic carbons

*p*-cymene aromatic carbons

Ligands carbons



Current Data Parameters  
NAME Dr. PP080320  
EXPNO 4  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20200308  
Time 19.20 h  
INSTRUM spect  
PROBHD Z108618\_0505 ( )  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 2000  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631488 sec  
RG 199.6  
DW 20.800 usec  
DE 6.50 usec  
TE 299.2 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TD0 1  
SFO1 100.6550186 MHz  
NUC1 13C  
P1 9.80 usec  
PLW1 58.0000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
PLW2 16.0000000 W  
PLW12 0.38716000 W  
PLW13 0.19474000 W



F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WMW RM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

11n

Signature SIF VIT VELLORE  
11L




9.186  
8.941  
8.921  
8.744  
8.722  
8.419  
8.399  
8.322  
8.302  
8.195  
8.175  
8.156  
8.045  
8.026  
8.007  
7.975  
7.557  
7.535  
5.891  
5.876  
5.811  
5.798  
5.769  
5.754  
3.485  
2.500  
2.365  
2.348  
2.331  
2.314  
2.297  
2.092  
0.899  
0.882  
0.829  
0.812



Current Data Parameters  
NAME Dr.FP161219  
EXPNO 19  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20191216  
Time 8.29 h  
INSTRUM spect  
PROBHD Z108618\_0505 ( )  
PULPROG zg30  
TD 65536  
SOLVENT DMSO  
DS 2  
SWH 8012.820 Hz  
FIDRES 0.244532 Hz  
AQ 4.0894465 sec  
RG 71.13  
DW 62.400 usec  
DE 6.50 usec  
TE 297.4 K  
D1 1.00000000 sec  
TDO 1  
SFO1 400.2604716 MHz  
NUC1 1H  
P1 14.00 usec  
PLW1 16.00000000 W



F2 - Processing parameters  
SI 65536  
SF 400.2580036 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00



11n



Signature SIF VIT VELLORE  
11L




Current Data Parameters  
NAME Dr.PP161213  
EXPNO 20  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20191216  
Time 10.25 h  
INSTRUM spect  
PROBHD Z108618\_0505 (  
PULPROG zgpg30  
TD 65536  
SOLVENT DMSO  
NS 2000  
DS 4  
SWH 24038.461 Hz  
FIDRES 0.733596 Hz  
AQ 1.3631489 sec  
RG 199.6  
DW 20.800 usec  
DE 6.50 usec  
TE 297.7 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TDO 1  
SFO1 100.6550186 MHz  
NUC1 13C  
P1 9.80 usec  
PLW1 58.0000000 W  
SFO2 400.2596010 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
PLW2 16.0000000 W  
PLW12 0.38716000 W  
PLW13 0.19474000 W

F2 - Processing parameters  
SI 32768  
SF 100.6449542 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40


**TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR  
516.08 [M<sup>+</sup>]**






### ESI-MS spectra of complex 11a

## TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 544.11 [M<sup>+</sup>]




### ESI-MS spectra of complex 11i

## TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 584.0 [M<sup>+</sup>]




**Figure S98- LC-MS spectra of complex 11j**

# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 550.0 [M<sup>+</sup>]




ESI-MS spectra of complex 11b

# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 534.10 [M<sup>+</sup>]




ESI-MS spectra of complex 11k

# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 593.99 [M<sup>+</sup>]




## ESI-MS spectra of complex 11

# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 584.06 [M<sup>+</sup>]




## ESI-MS spectra of complex 11d

### TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 546.09 [M<sup>+</sup>]




## ESI-MS spectra of complex 11e

### TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 561.06 [M<sup>+</sup>]




## ESI-MS spectra of complex 11f

# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 567.00 [M<sup>+</sup>]



ESI-MS spectra of complex 11h


# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 517.06 [M<sup>+</sup>]



ESI-MS spectra of complex 11m





# TOTAL ION CHROMATOGRAM AND MOLECULAR ION (Q1) FOR 594.97 [M<sup>+</sup>]





ESI-MS spectra of complex 11n


## Confirmation of Complex Formation by IR Spectroscopy




IR Spectra of ligand 3a (above) and complex 5a (below)





IR Spectra of ligand 7g2 (above) and complex 8g2 (below)




**IR Spectra of complex 8g1**




**IR Spectra of complex 8g3**



**IR Spectra of ligand 712 (above) and complex 812 (below)**




**IR Spectra of complex 813**




**IR Spectra of complex 814**








**IR Spectra of complex 8I6**



**IR Spectra of complex 8I7**



**IR Spectra of ligand 10a (above) and complex 11a (below)**



**IR Spectra of complex 11I**

## Single crystal X-ray data

**Table S3. Crystal data and structure refinement for 7I1.**

Identification code	shelx	
Empirical formula	C <sub>18</sub> H <sub>11</sub> Cl N <sub>2</sub> S	
Formula weight	322.80	
Temperature	296(2) K	
Wavelength	0.71073 Å	
Crystal system	Monoclinic	
Space group	P 21/c	
Unit cell dimensions	a = 11.565(3) Å	a = 90°.
	b = 11.256(3) Å	b = 100.628(11)°.
	c = 11.423(3) Å	g = 90°.
Volume	1461.5(6) Å <sup>3</sup>	
Z	4	
Density (calculated)	1.467 Mg/m <sup>3</sup>	
Absorption coefficient	0.400 mm <sup>-1</sup>	
F(000)	664	
Crystal size	0.150 x 0.120 x 0.100 mm <sup>3</sup>	
Theta range for data collection	2.547 to 33.814°.	
Index ranges	-17 ≤ h ≤ 17, -17 ≤ k ≤ 17, -17 ≤ l ≤ 17	
Reflections collected	42615	
Independent reflections	5814 [R(int) = 0.0772]	
Completeness to theta = 25.242°	99.7 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.7466 and 0.6349	
Refinement method	Full-matrix least-squares on F <sup>2</sup>	
Data / restraints / parameters	5814 / 0 / 199	
Goodness-of-fit on F <sup>2</sup>	1.021	
Final R indices [I > 2σ(I)]	R1 = 0.0441, wR2 = 0.0946	
R indices (all data)	R1 = 0.1269, wR2 = 0.1324	
Extinction coefficient	n/a	
Largest diff. peak and hole	0.229 and -0.247 e.Å <sup>-3</sup>	

**Table S4. Atomic coordinates (  $\times 10^4$ ) and equivalent isotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for rpbtz.  $U(\text{eq})$  is defined as one third of the trace of the orthogonalized  $U_{ij}$  tensor.**

	x	y	z	$U(\text{eq})$
C(1)	4925(2)	2398(2)	5073(2)	39(1)
C(2)	4082(2)	1743(2)	5531(2)	42(1)
C(3)	3504(2)	856(2)	4840(2)	43(1)
C(4)	3734(2)	577(2)	3713(2)	47(1)
C(5)	4573(2)	1215(2)	3266(2)	46(1)
C(6)	5162(2)	2127(2)	3941(2)	40(1)
C(7)	6229(2)	3802(2)	4974(2)	40(1)
C(8)	6978(2)	4849(2)	5304(2)	41(1)
C(9)	6918(2)	5477(2)	6337(2)	48(1)
C(10)	7644(2)	6443(2)	6599(2)	53(1)
C(11)	8403(2)	6738(2)	5850(2)	51(1)
C(12)	8433(2)	6063(2)	4835(2)	42(1)
C(13)	9282(2)	6298(2)	4032(2)	43(1)
C(14)	10031(2)	7278(2)	4184(2)	59(1)
C(15)	10853(2)	7445(2)	3459(2)	65(1)
C(16)	10951(2)	6659(2)	2575(2)	58(1)
C(17)	10208(2)	5693(2)	2406(2)	59(1)
C(18)	9388(2)	5515(2)	3128(2)	51(1)
N(1)	5543(1)	3350(1)	5641(1)	43(1)
N(2)	7708(1)	5126(1)	4561(1)	42(1)
S(1)	6212(1)	3106(1)	3602(1)	46(1)
Cl(1)	2413(1)	57(1)	5367(1)	63(1)

**Table S5. Bond lengths [Å] and angles [°] for 7I1.**

---

C(1)-N(1)	1.382(2)
C(1)-C(2)	1.399(2)
C(1)-C(6)	1.403(2)
C(2)-C(3)	1.368(3)
C(2)-H(2)	0.9300
C(3)-C(4)	1.398(3)
C(3)-Cl(1)	1.7435(19)
C(4)-C(5)	1.379(3)
C(4)-H(4)	0.9300
C(5)-C(6)	1.385(3)
C(5)-H(5)	0.9300
C(6)-S(1)	1.7359(18)
C(7)-N(1)	1.300(2)
C(7)-C(8)	1.470(3)
C(7)-S(1)	1.7487(18)
C(8)-N(2)	1.340(2)
C(8)-C(9)	1.388(3)
C(9)-C(10)	1.373(3)
C(9)-H(9)	0.9300
C(10)-C(11)	1.374(3)
C(10)-H(10)	0.9300
C(11)-C(12)	1.392(3)
C(11)-H(11)	0.9300
C(12)-N(2)	1.348(2)
C(12)-C(13)	1.486(3)
C(13)-C(18)	1.380(3)
C(13)-C(14)	1.394(3)
C(14)-C(15)	1.383(3)
C(14)-H(14)	0.9300
C(15)-C(16)	1.363(3)
C(15)-H(15)	0.9300
C(16)-C(17)	1.377(3)
C(16)-H(16)	0.9300
C(17)-C(18)	1.382(3)
C(17)-H(17)	0.9300
C(18)-H(18)	0.9300
N(1)-C(1)-C(2)	124.66(16)



N(1)-C(1)-C(6)	115.40(15)
C(2)-C(1)-C(6)	119.90(17)
C(3)-C(2)-C(1)	117.98(16)
C(3)-C(2)-H(2)	121.0
C(1)-C(2)-H(2)	121.0
C(2)-C(3)-C(4)	122.62(17)
C(2)-C(3)-Cl(1)	119.02(14)
C(4)-C(3)-Cl(1)	118.35(15)
C(5)-C(4)-C(3)	119.41(18)
C(5)-C(4)-H(4)	120.3
C(3)-C(4)-H(4)	120.3
C(4)-C(5)-C(6)	119.16(17)
C(4)-C(5)-H(5)	120.4
C(6)-C(5)-H(5)	120.4
C(5)-C(6)-C(1)	120.93(16)
C(5)-C(6)-S(1)	129.72(14)
C(1)-C(6)-S(1)	109.33(13)
N(1)-C(7)-C(8)	123.88(16)
N(1)-C(7)-S(1)	116.27(14)
C(8)-C(7)-S(1)	119.83(13)
N(2)-C(8)-C(9)	123.81(18)
N(2)-C(8)-C(7)	115.74(16)
C(9)-C(8)-C(7)	120.45(17)
C(10)-C(9)-C(8)	117.63(19)
C(10)-C(9)-H(9)	121.2
C(8)-C(9)-H(9)	121.2
C(9)-C(10)-C(11)	119.4(2)
C(9)-C(10)-H(10)	120.3
C(11)-C(10)-H(10)	120.3
C(10)-C(11)-C(12)	120.23(19)
C(10)-C(11)-H(11)	119.9
C(12)-C(11)-H(11)	119.9
N(2)-C(12)-C(11)	120.67(18)
N(2)-C(12)-C(13)	116.70(17)
C(11)-C(12)-C(13)	122.59(17)
C(18)-C(13)-C(14)	117.35(19)
C(18)-C(13)-C(12)	120.58(17)
C(14)-C(13)-C(12)	122.02(19)
C(15)-C(14)-C(13)	120.9(2)
C(15)-C(14)-H(14)	119.5

C(13)-C(14)-H(14)	119.5
C(16)-C(15)-C(14)	121.0(2)
C(16)-C(15)-H(15)	119.5
C(14)-C(15)-H(15)	119.5
C(15)-C(16)-C(17)	118.8(2)
C(15)-C(16)-H(16)	120.6
C(17)-C(16)-H(16)	120.6
C(16)-C(17)-C(18)	120.7(2)
C(16)-C(17)-H(17)	119.7
C(18)-C(17)-H(17)	119.7
C(13)-C(18)-C(17)	121.3(2)
C(13)-C(18)-H(18)	119.4
C(17)-C(18)-H(18)	119.4
C(7)-N(1)-C(1)	110.29(15)
C(8)-N(2)-C(12)	118.21(16)
C(6)-S(1)-C(7)	88.68(9)

---

Symmetry transformations used to generate equivalent atoms:

**Table S6. Anisotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for rpbzt. The anisotropic displacement factor exponent takes the form:  $-2p^2 [h^2 a^2 U_{11} + \dots + 2 h k a^* b^* U_{12}]$**

	U <sub>11</sub>	U <sub>22</sub>	U <sub>33</sub>	U <sub>23</sub>	U <sub>13</sub>	U <sub>12</sub>
C(1)	40(1)	44(1)	33(1)	3(1)	9(1)	3(1)
C(2)	46(1)	51(1)	32(1)	3(1)	13(1)	-2(1)
C(3)	43(1)	45(1)	42(1)	6(1)	13(1)	-1(1)
C(4)	56(1)	42(1)	44(1)	-4(1)	12(1)	-2(1)
C(5)	57(1)	47(1)	40(1)	-3(1)	20(1)	2(1)
C(6)	43(1)	42(1)	36(1)	3(1)	15(1)	4(1)
C(7)	40(1)	43(1)	38(1)	3(1)	9(1)	4(1)
C(8)	37(1)	42(1)	42(1)	6(1)	6(1)	5(1)
C(9)	45(1)	53(1)	48(1)	-1(1)	10(1)	5(1)
C(10)	52(1)	54(1)	53(1)	-11(1)	7(1)	5(1)
C(11)	45(1)	45(1)	60(1)	-5(1)	5(1)	-1(1)
C(12)	37(1)	37(1)	48(1)	2(1)	2(1)	4(1)
C(13)	37(1)	40(1)	50(1)	6(1)	3(1)	4(1)
C(14)	62(1)	50(1)	65(1)	-1(1)	13(1)	-10(1)
C(15)	59(1)	58(1)	78(2)	9(1)	13(1)	-17(1)
C(16)	46(1)	63(1)	68(1)	15(1)	15(1)	-1(1)
C(17)	54(1)	59(1)	68(1)	-1(1)	21(1)	1(1)
C(18)	44(1)	47(1)	65(1)	-1(1)	14(1)	-4(1)
N(1)	45(1)	51(1)	36(1)	-1(1)	11(1)	-4(1)
N(2)	41(1)	40(1)	44(1)	3(1)	7(1)	1(1)
S(1)	53(1)	47(1)	42(1)	2(1)	22(1)	-3(1)
Cl(1)	63(1)	69(1)	60(1)	2(1)	23(1)	-21(1)

**Table S7. Hydrogen coordinates (  $\times 10^4$ ) and isotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for 7I1.**

	x	y	z	U(eq)
H(2)	39201905	628251		
H(4)	3325-34	326956		
H(5)	47401036	252056		
H(9)	64045251	683458		
H(10)	76226893	727764		
H(11)	88977391	602261		
H(14)	99787826	478071		
H(15)	113478104	357878		
H(16)	115096774	209570		
H(17)	102585156	179971		
H(18)	88984853	300362		

**Table S8. Torsion angles [°] for 711.**

---

N(1)-C(1)-C(2)-C(3)	177.05(17)
C(6)-C(1)-C(2)-C(3)	-0.6(3)
C(1)-C(2)-C(3)-C(4)	0.8(3)
C(1)-C(2)-C(3)-Cl(1)	-177.90(14)
C(2)-C(3)-C(4)-C(5)	-0.2(3)
Cl(1)-C(3)-C(4)-C(5)	178.47(15)
C(3)-C(4)-C(5)-C(6)	-0.5(3)
C(4)-C(5)-C(6)-C(1)	0.7(3)
C(4)-C(5)-C(6)-S(1)	-177.65(15)
N(1)-C(1)-C(6)-C(5)	-177.99(17)
C(2)-C(1)-C(6)-C(5)	-0.1(3)
N(1)-C(1)-C(6)-S(1)	0.7(2)
C(2)-C(1)-C(6)-S(1)	178.52(14)
N(1)-C(7)-C(8)-N(2)	174.08(17)
S(1)-C(7)-C(8)-N(2)	-6.9(2)
N(1)-C(7)-C(8)-C(9)	-5.0(3)
S(1)-C(7)-C(8)-C(9)	173.92(14)
N(2)-C(8)-C(9)-C(10)	0.6(3)
C(7)-C(8)-C(9)-C(10)	179.70(17)
C(8)-C(9)-C(10)-C(11)	-0.9(3)
C(9)-C(10)-C(11)-C(12)	0.0(3)
C(10)-C(11)-C(12)-N(2)	1.2(3)
C(10)-C(11)-C(12)-C(13)	-176.38(18)
N(2)-C(12)-C(13)-C(18)	-6.3(3)
C(11)-C(12)-C(13)-C(18)	171.31(18)
N(2)-C(12)-C(13)-C(14)	176.36(18)
C(11)-C(12)-C(13)-C(14)	-6.0(3)
C(18)-C(13)-C(14)-C(15)	-0.6(3)
C(12)-C(13)-C(14)-C(15)	176.8(2)
C(13)-C(14)-C(15)-C(16)	0.2(4)
C(14)-C(15)-C(16)-C(17)	0.5(4)
C(15)-C(16)-C(17)-C(18)	-0.8(3)
C(14)-C(13)-C(18)-C(17)	0.2(3)
C(12)-C(13)-C(18)-C(17)	-177.21(19)
C(16)-C(17)-C(18)-C(13)	0.5(3)
C(8)-C(7)-N(1)-C(1)	178.07(16)
S(1)-C(7)-N(1)-C(1)	-0.9(2)
C(2)-C(1)-N(1)-C(7)	-177.60(17)

C(6)-C(1)-N(1)-C(7)	0.1(2)
C(9)-C(8)-N(2)-C(12)	0.5(3)
C(7)-C(8)-N(2)-C(12)	-178.57(15)
C(11)-C(12)-N(2)-C(8)	-1.4(3)
C(13)-C(12)-N(2)-C(8)	176.27(15)
C(5)-C(6)-S(1)-C(7)	177.57(19)
C(1)-C(6)-S(1)-C(7)	-0.93(14)
N(1)-C(7)-S(1)-C(6)	1.12(15)
C(8)-C(7)-S(1)-C(6)	-177.92(15)

---

Symmetry transformations used to generate equivalent atoms:



**Table S9. Hydrogen bonds for 7I2 [Å and °].**

---

D-H...A	d(D-H)	d(H...A)	d(D...A)	<(DHA)
C(5)-H(5)...N(1)#1	0.93	2.59	3.425(2)	150.5

---

—  
Symmetry transformations used to generate equivalent atoms:

#1 x,-y+1/2,z-1/2

**Characterization data for some selected ligands (3a, 3l, 10a, and 10l) and complexes (5a-5l and 11a-11n):**

**2-(6-bromopyridin-2-yl)-1H-benzo[d]imidazole (3a):** Yield: 95%;  $R_f$  (25% ethylacetate in hexane): 0.23; IR ( $\text{cm}^{-1}$ ):  $\nu$  3047, 1585, 1550, 1438, 1409, 1315, 983, 740;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 7.30-7.33 (m, 3H, ArCH), 7.52 (dd,  $J_1 = 0.8$  Hz,  $J_2 = 8.0$  Hz 2H, ArCH), 7.69 (t,  $J = 8.0$  Hz, 1H, ArCH), 8.37 (dd,  $J_1 = 0.8$  Hz,  $J_2 = 7.6$ , 1H, ArCH), 10.55 (br s, 1H, ArNH); ESI-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  273.99  $[\text{M}+\text{H}]^+$ .

**$[(\eta^6\text{-}p\text{-cymene})\text{RuCl}\{2\text{-(6-bromopyridin-2-yl)-1H-benzo[d]imidazole}\}\text{Cl}$  (5a):**

123.41 mg (0.021 mmol, 92%);  $Mr$  ( $\text{C}_{22}\text{H}_{22}\text{N}_3\text{BrCl}_2\text{Ru}$ ) = 583.31 g/mol; Anal. Calcd. for  $\text{C}_{22}\text{H}_{22}\text{N}_3\text{BrCl}_2\text{Ru}$  (%): C 45.53, H 3.82, N 7.24. Found: C 45.23, H 3.38, N 6.86; Mp: 224-226°C decomp.;  $R_f$  (100% ethyl acetate): 0.28; IR ( $\text{cm}^{-1}$ ):  $\nu$  3445, 3047, 2966, 1602, 1473, 1423, 993, 744;  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  (ppm) 0.82-0.88 (brm, 6H,  $p\text{-cymCH}_3$ , H-i, H-j), 2.24 (s, 3H,  $p\text{-cymCH}_3$ , H-a), 2.79-2.86 (m, 1H,  $p\text{-cym CH}$ , H-h), 6.05 (d,  $J = 8.0$  Hz, 1H,  $p\text{-cym ArCH}$ , H-f), 6.21 (d,  $J = 8.0$  Hz, 1H,  $p\text{-cym ArCH}$ , H-e), 6.28 (d,  $J = 5.2$  Hz, 1H,  $p\text{-cym ArCH}$ , H-d), 6.46 (d,  $J = 5.6$  Hz, 1H,  $p\text{-cym ArCH}$ , H-c), 7.55-7.62 (m, 2H, ArCH, H-2, H-3), 7.83 (d,  $J = 7.2$  Hz, 1H, ArCH, H-1), 8.03 (d,  $J = 8.0$  Hz, 1H, ArCH, H-4), 8.17 (d,  $J = 6.0$  Hz, 2H, ArCH, H-10, H-11), 8.55-8.57 (m, 1H, ArCH, H-9);  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  18.3 (Me, C-a,  $p\text{-cymene}$ ), 21.9 (Me, C-i,  $p\text{-cymene}$ ), 27.3 (Me, C-j,  $p\text{-cymene}$ ), 30.5 (CH, C-h,  $p\text{-cymene}$ ), 85.3 (ArCH, C-f,  $p\text{-cymene}$ ), 85.9 (ArCH, C-e,  $p\text{-cymene}$ ), 86.8 (ArCH, C-d,  $p\text{-cymene}$ ), 87.5 (ArCH, C-c,  $p\text{-cymene}$ ), 100.7 (ArC, C-g,  $p\text{-cymene}$ ), 107.1 (ArC, C-b,  $p\text{-cymene}$ ), 123.1 (ArCH, C-4), 124.6 (ArCH, C-1), 126.6 (ArCH, C-3), 127.3 (ArCH, C-2), 129.3 (ArCH, C-9), 131.9 (ArCH, C-11), 134.8 (ArC, C-6), 139.9 (ArC, C-5), 141.7 (ArCH, C-10), 150.7 (ArC, C-7), 155.0 (ArC, C-12), 165.6 (ArC, C-8); ESI-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  543.97  $[\text{M-Cl}]^+$ .

**$[(\eta^6\text{-}p\text{-cymene})\text{RuCl}\{2\text{-(6-bromopyridin-2-yl)-5-chloro-1H-benzo[d]imidazole}\}\text{Cl}$  (5b):**

49.5 mg (0.081 mmol, 46 %);  $Mr$  ( $\text{C}_{22}\text{H}_{22}\text{N}_3\text{BrCl}_2\text{Ru}$ ) = 614.75 g/mol; Anal. Calcd. for  $\text{C}_{22}\text{H}_{21}\text{N}_3\text{BrCl}_3\text{Ru}$  (%): C 42.98, H 3.44, N 6.84. Found: C 42.71, H 3.67, N 6.69.; Mp: 225-228°C decomp.;  $R_f$  (100% ethyl acetate): 0.25; IR ( $\text{cm}^{-1}$ ):  $\nu$  3441, 3045, 2963, 1600, 1453, 1413, 990, 742;  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  (ppm) 0.99 (d, 3H,  $J = 6.8$  Hz,  $p\text{-cymCH}_3$ , H-j), 1.09 (d, 3H,  $J = 6.8$  Hz,  $p\text{-cymCH}_3$ , H-i), 2.22 (s, 3H,  $p\text{-cym CH}_3$ , H-a), 2.66-2.69 (m, 1H,  $p\text{-cym CH}$ , H-h), 5.26 (brs, 1H,  $p\text{-cym ArH}$ , H-f), 5.53 (d, 1H,  $J = 5.6$  Hz,  $p\text{-cym ArH}$ , H-e), 5.71 (d, 1H,  $J = 6.0$  Hz,  $p\text{-cym ArCH}$ , H-d), 6.10 (brs, 1H,  $p\text{-cym ArH}$ , H-c), 7.02 (t, 1H,  $J = 7.6$  Hz, ArH, H-2), 7.24 (d,  $J = 8.0$  Hz, 1H, ArH, H-1), 7.34 (t, 1H,  $J = 8.0$  Hz, ArH, H-11), 8.14 (t, 1H,  $J = 7.2$  Hz, ArH, H-10), 8.29 (d,  $J = 6.8$  Hz, ArH, H-9), 8.96 (s, 1H, ArH, H-4), 10.98 (s, 1H, ArNH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  19.1 (Me, C-a,  $p\text{-cymene}$ ), 21.8 (Me, C-j,  $p\text{-cymene}$ ), 22.7 (Me, C-i,  $p\text{-cymene}$ ), 31.2 (CH, C-h,  $p\text{-cymene}$ ), 79.1 (ArCH, C-f,  $p\text{-cymene}$ ), 79.4 (ArCH, C-e,  $p\text{-cymene}$ ), 79.8 (ArCH, C-d,  $p\text{-cymene}$ ), 80.6 (ArCH, C-c,  $p\text{-cymene}$ ), 101.2 (ArC, C-g,  $p\text{-cymene}$ ), 104.6 (ArC, C-b,  $p\text{-cymene}$ ), 117.6 (ArCH, C-1), 119.9 (ArCH, C-4), 121.5 (ArCH, C-2), 125.3 (ArCH, C-9), 129.7 (ArCH, C-11), 130.7 (ArC, C-3), 134.8 (ArC, C-5), 139.6 (ArCH, C-10), 141.9 (ArC, C-6), 147.5 (ArC, C-7), 149.6 (ArC, C-12), 156.4 (ArC, C-8); ESI-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  577.93  $[\text{M-Cl}]^+$ .

**$[(\eta^6\text{-}p\text{-cymene})\text{RuCl}\{2\text{-(6-bromopyridin-2-yl)-6-chloro-1H-benzo[d]imidazole}\}\text{Cl}$  (5b'):**

47.4 mg (0.077 mmol, 44 %);  $Mr$  ( $\text{C}_{22}\text{H}_{22}\text{N}_3\text{BrCl}_2\text{Ru}$ ) = 614.75 g/mol; Anal. Calcd. for  $\text{C}_{22}\text{H}_{21}\text{N}_3\text{BrCl}_3\text{Ru}$  (%): C 42.98, H 3.44, N 6.84. Found: C 42.69, H 3.71, N 6.63.; Mp: 225-228°C decomp.;  $R_f$  (100% ethyl acetate): 0.22; IR ( $\text{cm}^{-1}$ ):  $\nu$  3441, 3045, 2963, 1600, 1453, 1413, 990, 742;  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  (ppm) 0.99 (d, 3H,  $J = 6.8$  Hz,  $p\text{-cymCH}_3$ , H-j), 1.08 (d, 3H,  $J = 6.8$  Hz,  $p\text{-cymCH}_3$ , H-i), 2.22 (s, 3H,  $p\text{-cym CH}_3$ , H-a), 2.65-2.69 (m, 1H,  $p\text{-cym CH}$ , H-h), 5.26 (brs, 1H,  $p\text{-cym ArH}$ , H-f), 5.53 (d, 1H,  $J = 5.6$  Hz,  $p\text{-cym ArH}$ , H-e), 5.71 (d, 1H,  $J =$

5.6 Hz, *p*-cym ArH, H-d), 6.09 (brs, 1H, *p*-cym ArH, H-c), 7.02 (t, 1H, *J* = 7.6 Hz, ArH, H-3), 7.24 (d, 1H, *J* = 8.0 Hz, ArH, H-4), 7.34 (t, 1H, *J* = 7.6 Hz, ArH, H-11), 8.14 (t, 1H, *J* = 7.2 Hz, ArH, H-10), 8.25 (d, 1H, *J* = 7.6 Hz, H-9), 8.96 (s, 1H, ArH, H-1), 10.88 (s, 1H, ArNH); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 19.2 (Me, C-a, *p*-cymene), 21.8 (Me, C-j, *p*-cymene), 22.8 (Me, C-i, *p*-cymene), 31.2 (CH, C-h, *p*-cymene), 78.5 (ArCH, C-f, *p*-cymene), 79.2 (ArCH, C-e, *p*-cymene), 79.8 (ArCH, C-d, *p*-cymene), 80.9 (ArCH, C-c, *p*-cymene), 101.5 (ArC, C-g, *p*-cymene), 106.1 (ArC, C-b, *p*-cymene), 117.6 (ArCH, C-4), 120.0 (ArCH, C-1), 121.4 (ArCH, C-3), 125.4 (ArCH, C-9), 129.8 (ArCH, C-11), 130.8 (ArC, C-2), 134.9 (ArC, C-6), 139.6 (ArCH, C-10), 142.0 (ArC, C-5), 147.5 (ArC, C-7), 149.7 (ArC, C-12), 156.5 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 577.93 [M-Cl]<sup>+</sup>.

**[(*η*<sup>6</sup>-*p*-cymene)RuCl{2-(6-bromopyridin-2-yl)-5-chloro-6-fluoro-1H-benzo[d]imidazole}]Cl**

**(5c)**: 45.30 mg (0.072 mmol, 46%); *Mr* (C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>BrCl<sub>3</sub>FRu) = 632.74 g/mol; Anal. Calcd. for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>BrCl<sub>3</sub>FRu (%): C 41.76, H 3.19, N 6.64. Found: C 41.41, H 3.48, N 6.71; Mp: 226-228°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.20; IR (cm<sup>-1</sup>): ν 3444, 3051, 2958, 1607, 1454, 1414, 991, 743; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sup>6</sup>): δ (ppm) = 1.18 (d, 6H, *J* = 6.8 Hz, *p*-cym CH<sub>3</sub>, Hi, Hj), 2.08 (s, 3H, *p*-cymCH<sub>3</sub>, Ha), 2.79-2.87 (m, 1H, *p*-cymCH, Hh), 5.76 (d, 2H, *J* = 6.4 Hz, *p*-cym ArH, He, Hf), 5.81 (d, 2H, *J* = 6.8 Hz, *p*-cym ArH, Hc, Hd), 7.63 (d, 1H, *J* = 9.2 Hz, ArH, H1), 7.80 (t, 1H, *J* = 8 Hz, ArH, H11), 7.93-7.99 (m, 1H, ArH, H10), 8.14 (s, 1H, ArH, H4), 8.30 (d, 2H, *J* = 7.6 Hz, ArH, H9); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-i, C-j, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 85.4 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.5 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 115.9 (ArCH, C-1), 121.5 (ArCH, C-3), 122.5 (ArC, C-4), 129.9 (ArCH, C-9), 132.6 (ArCH, C-11), 135.3 (ArC, C-6), 141.4 (ArC, C-5), 141.7 (ArCH, C-10), 144.8 (ArC, C-7), 148.5 (ArC, C-12), 149.3 (ArC, C-2), 151.7 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 595.92 [M-Cl]<sup>+</sup>.

**[(*η*<sup>6</sup>-*p*-cymene)RuCl{2-(6-bromopyridin-2-yl)-5-fluoro-6-chloro-1H-benzo[d]imidazole}]Cl**

**(5c)**: 43.34 mg (0.069 mmol, 44%); *Mr* (C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>BrCl<sub>3</sub>FRu) = 632.74 g/mol; Anal. Calcd. for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>BrCl<sub>3</sub>FRu (%): C 41.76, H 3.19, N 6.64. Found: C 41.49, H 3.36, N 6.72; Mp: 227-229°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.22; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sup>6</sup>): δ (ppm) = 1.19 (d, 6H, *J* = 7.2 Hz, *p*-cym CH<sub>3</sub>, Hi, Hj), 2.08 (s, 3H, *p*-cymCH<sub>3</sub>, Ha), 2.83 (sept, 1H, *J* = 6.8 Hz, *p*-cymCH, Hh), 6.01 (d, 1H, *J* = 5.2 Hz, *p*-cym ArH, Hf), 6.20 (d, 2H, *J* = 6.4 Hz, *p*-cym ArH, He), 6.30 (d, 2H, *J* = 8.0 Hz, *p*-cym ArH, Hd), 6.43 (d, 2H, *J* = 4.4 Hz, *p*-cym ArH, He), 7.82 (d, 1H, *J* = 9.2 Hz, ArH, H4), 7.93-7.96 (m, 1H, ArH, H11), 8.12 (s, 1H, ArH, H1), 8.31 (d, 1H, *J* = 7.6 Hz, ArCH, H9), 8.40-8.43 (m, 1H, ArH, H10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.2 (Me, C-a, *p*-cymene), 21.9 (Me, C-i, C-j, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 85.1 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.5 (ArCH, C-c, *p*-cymene), 100.5 (ArC, C-g, *p*-cymene), 106.8 (ArC, C-b, *p*-cymene), 115.9 (ArCH, C-4), 121.4 (ArC, C-2), 122.4 (ArCH, C-1), 129.8 (ArCH, C-11), 132.5 (ArCH, C-9), 134.4 (ArC, C-5), 141.3 (ArC, C-6), 141.7 (ArCH, C-10), 141.9 (ArC, C-7), 144.8 (ArC, C-12), 149.2 (ArC, C-3), 151.6 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 595.92 [M-Cl]<sup>+</sup>.

**[(*η*<sup>6</sup>-*p*-cymene)RuCl{2-(6-bromopyridin-2-yl)-5-(trifluoromethyl)-1H-benzo[d]imidazole}]Cl**

**(5d)**: 43.2 mg (0.067 mmol, 47 %); *Mr* (C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>BrCl<sub>2</sub>F<sub>3</sub>Ru) = 648.31 g/mol; Anal. calcd for C<sub>23</sub>H<sub>21</sub>BrCl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>Ru (%): C 42.61, H 3.26, N 6.48. Found: C 42.29, H 3.54, N 6.13.; Mp: 222-224°C; R<sub>f</sub> (100% ethyl acetate): 0.26; Mp: 222-224°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.22; IR (cm<sup>-1</sup>): ν 3443, 3047, 2958, 1600, 1456, 1415, 1321, 991, 743; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.79 (d, 3H, *J* = 5.2 Hz, *p*-cymCH<sub>3</sub>, H-j), 0.82 (d, 3H, *J* = 6.8 Hz, *p*-cymCH<sub>3</sub>, H-i), 2.31 (s, *p*-cymCH<sub>3</sub>, H-a), 2.43 (brs, 1H, *p*-*p*-cym CH, H-h), 5.62 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-f), 5.66 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-e), 5.77 (d, 1H, *J* = 5.2

Hz, *p*-cym ArH, H-d), 5.95 (d, 1H, *J* = 6.4 Hz, *p*-cym ArH, H-c), 7.42 (d, 1H, *J* = 8.0 Hz, ArH, H-12), 7.56 (d, 1H, *J* = 8.0 Hz, ArH, H-11), 7.61-7.68 (m, 2H, ArH, H-2, H-4), 8.03 (s, 1H, ArH, H-10), 8.31 (d, 1H, *J* = 8.2 Hz, H-9); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-i, *p*-cymene), 24.4 (Me, C-j, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 85.0 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.8 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 119.0 (ArCH, C-1, C-4), 122.1 (ArCH, C-2), 126.5 (ArCH, C-9), 129.3 (ArC, C-13), 130.5 (ArC, C-3), 135.0 (ArCH, C-11), 141.5 (ArC, C-6), 141.9 (ArCH, C-10), 143.7 (ArC, C-7), 145.7 (ArC, C-5), 148.9 (ArC, C-12), 153.8 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 611.97 [M-Cl]<sup>+</sup>;

**[(*η*<sup>6</sup>-*p*-cymene)RuCl<sub>2</sub>(2-(6-bromopyridin-2-yl)-6-(trifluoromethyl)-1H-benzo[d]imidazole)]Cl (5d<sup>+</sup>):**

40.5 mg (0.062 mmol, 44 %); *Mr* (C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>BrCl<sub>2</sub>F<sub>3</sub>Ru) = 648.31 g/mol; Anal. calcd for C<sub>23</sub>H<sub>21</sub>BrCl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>Ru (%): C 42.61, H 3.26, N 6.48. Found: C 42.38, H 3.47, N 6.20; Mp: 223-226°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.18; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.80 (d, 3H, *J* = 4.0 Hz, *p*-cymCH<sub>3</sub>, H-j), 0.82 (d, 3H, *J* = 6.4 Hz, *p*-cymCH<sub>3</sub>, H-i), 2.31 (s, *p*-cymCH<sub>3</sub>, H-a), 2.44 (brs, 1H, *p*-*p*-cym CH, H-h), 5.62 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-f), 5.66 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-e), 5.77 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-d), 5.95 (d, 1H, *J* = 6.8 Hz, *p*-cym ArH, H-c), 7.43 (d, 1H, *J* = 7.6 Hz, ArH, H-4), 7.56 (d, 1H, *J* = 8.4 Hz, ArH, H-11), 7.61-7.68 (m, 2H, ArH, H-3, H-1), 8.03 (s, 1H, ArH, H-10), 8.31 (d, 1H, *J* = 7.2 Hz, H-9); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 22.1 (Me, C-i, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 85.3 (ArCH, C-f, *p*-cymene), 86.0 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.5 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 120.0 (ArCH, C-1), 121.8 (ArCH, C-4), 122.5 (ArCH, C-3), 124.0 (ArCH, C-9), 126.7 (ArC, C-13), 130.1 (ArC, C-2), 137.0 (ArCH, C-11), 140.7 (ArC, C-5), 141.2 (ArC, C-6), 141.4 (ArC, C-7), 141.8 (ArCH, C-10), 149.3 (ArC, C-12), 152.0 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 611.97 [M-Cl]<sup>+</sup>.

**[(*η*<sup>6</sup>-*p*-cymene)Ru-2-(6-bromopyridin-2-yl)-5-methoxy-1H-benzo[d]imidazole]Cl (5e):**

49.5 mg (0.081 mmol, 45 %); *Mr* (C<sub>23</sub>H<sub>24</sub>N<sub>3</sub>OBrCl<sub>2</sub>Ru) = 610.34 g/mol; Anal. calcd for C<sub>23</sub>H<sub>24</sub>BrCl<sub>2</sub>N<sub>3</sub>ORu (%): C 45.26, H 3.96, N 6.88. Found: C 45.01, H 3.77, N 7.02.; Mp: 222-224°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.30; Mp: 231-232°C; R<sub>f</sub> (100% ethyl acetate): 0.06; IR (cm<sup>-1</sup>): ν 3445, 3126, 3048, 2958, 1694, 1600, 1457, 1425, 1324, 990, 744; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.87 (d, 3H, *J* = 6.8 Hz, *p*-cymCH<sub>3</sub>, H-j), 0.92 (d, 3H, *J* = 6.8 Hz, *p*-cymCH<sub>3</sub>, H-i), 2.32 (s, *p*-cymCH<sub>3</sub>, H-a), 2.82-2.89 (m, 1H, *p*-cym CH, H-h), 3.86 (s, 3H, -OMe, H-13), 5.28 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-f), 5.41 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-e), 5.78 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-d), 6.02 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-c), 7.04 (d, 1H, *J* = 7.2 Hz, ArH, H-2), 7.36 (s, 1H, ArH, H-4), 7.43 (d, 1H, *J* = 8.8 Hz, ArH, H-11), 7.69 (d, 1H, *J* = 8.0 Hz, ArH, H-1), 7.82-7.88 (m, 2H, H-9, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ (solubility problem); ESI-MS (CH<sub>3</sub>OH): *m/z* 573.98 [M-Cl]<sup>+</sup>

**[(*η*<sup>6</sup>-*p*-cymene)Ru-2-(6-bromopyridin-2-yl)-6-methoxy-1H-benzo[d]imidazole]Cl (5e<sup>+</sup>):**

53.0 mg (0.087 mmol, 48 %); *Mr* (C<sub>23</sub>H<sub>24</sub>N<sub>3</sub>OBrCl<sub>2</sub>Ru) = 610.34 g/mol; Anal. calcd for C<sub>23</sub>H<sub>24</sub>BrCl<sub>2</sub>N<sub>3</sub>ORu (%): C 45.26, H 3.96, N 6.88. Found: C 45.12, H 3.72, N 7.04.; Mp: 222-224°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.34; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.92 (d, 6H, *J* = 6.8 Hz, *p*-cymCH<sub>3</sub>, H-i, H-j), 2.32 (s, *p*-cymCH<sub>3</sub>, H-a), 2.83 (sept, 1H, *p*-cym CH, H-h), 3.86 (s, 3H, -OMe, H-13), 5.28 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-f), 5.41 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-e), 5.78 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-d), 6.02 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-c), 7.04 (d, 1H, *J* = 7.2 Hz, ArH, H-3), 7.36 (s, 1H, ArH, H-1), 7.44 (d, 1H, *J* = 8.8 Hz, ArH, H-11), 7.68 (d, 1H, *J* = 8.0 Hz, ArH, H-4), 7.83-7.88 (m, 2H, H-9, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ (solubility problem); ESI-MS (CH<sub>3</sub>OH): *m/z* 573.98 [M-Cl]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl{2-(6-bromopyridin-2-yl)-5-nitro-1H-benzo[d]imidazole}]Cl (5f):**

49.00 mg (0.078 mmol, 48 %); *Mr* (C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>BrCl<sub>2</sub>F<sub>3</sub>Ru) = 625.31 g/mol; Anal. calcd for C<sub>22</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub>BrCl<sub>2</sub>Ru (%): C 42.26, H 3.38, N 8.96. Found: C 42.54, H 3.59, N 8.63.; Mp: 222-224°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.26; Mp: 226-228°C; R<sub>f</sub> (100% ethyl acetate): 0.17; IR (cm<sup>-1</sup>):  $\nu$  3444, 3043, 2962, 1601, 1455, 1417, 1324, 995, 742; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 0.77 (d, 3H, *J* = 8.0 Hz, *p*-cymCH<sub>3</sub>, H-j), 0.80 (d, 3H, *J* = 6.8 Hz, *p*-cymCH<sub>3</sub>, H-i), 2.32 (s, *p*-cymCH<sub>3</sub>, H-a), 2.45 (brs, 1H, *p*-*p*-cym CH, H-h), 5.62 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-f), 5.67 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-e), 5.76 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-d), 5.96 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-c), 7.51 (d, 1H, *J* = 8.8 Hz, ArH, H-11), 7.67 (d, 2H, *J* = 7.2 Hz, ArH, H-10, H-1), 8.13 (d, 1H, *J* = 9.2 Hz, ArH, H-2), 8.34 (d, 1H, *J* = 6.8 Hz, ArH, H-9), 8.68 (s, 1H, H-4); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  18.3 (Me, C-a, *p*-cymene), 21.8 (Me, C-j, *p*-cymene), 21.9 (Me, C-i, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 85.1 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.5 (ArCH, C-c, *p*-cymene), 100.5 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 119.0 (ArCH, C-4), 119.5 (ArCH, C-1), 120.3 (ArCH, C-2), 122.1 (ArCH, C-9), 130.5 (ArCH, C-11), 138.7 (ArC, C-6), 141.5 (ArCH, C-10), 141.9 (ArC, C-7), 143.7 (ArC, C-12), 148.9 (ArC, C-3), 153.8 (ArC, C-5), 162.7 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 588.96 [M-Cl]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl{2-(6-bromopyridin-2-yl)-6-nitro-1H-benzo[d]imidazole}]Cl (5f')**: 43.89 mg (0.070 mmol, 43 %); *Mr* (C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>BrCl<sub>2</sub>F<sub>3</sub>Ru) = 625.31 g/mol; Anal. calcd for C<sub>22</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub>BrCl<sub>2</sub>Ru (%): C 42.26, H 3.38, N 8.96. Found: C 42.51, H 3.54, N 8.75.; Mp: 226-228°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.14; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 0.83 (d, 3H, *J* = 13.6 Hz, *p*-cymCH<sub>3</sub>, H-j), 0.87 (d, 3H, *J* = 6.4 Hz, *p*-cymCH<sub>3</sub>, H-i), 2.39 (s, *p*-cymCH<sub>3</sub>, H-a), 2.54 (brs, 1H, *p*-*p*-cym CH, H-h), 5.67 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-f), 5.77 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-e), 5.82 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-d), 5.87 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-c), 7.56 (d, 1H, *J* = 5.2 Hz, ArH, H-11), 7.73 (t, 2H, *J* = 7.2 Hz, ArH, H-10, H-4), 8.15-8.20 (m, 1H, ArH, H-3), 8.39 (d, 1H, *J* = 6.8 Hz, ArH, H-9), 8.50 (s, 1H, H-1); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 24.4 (Me, C-i, *p*-cymene), 30.5 (CH, C-h, *p*-cymene), 84.9 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.9 (ArCH, C-c, *p*-cymene), 100.7 (ArC, C-g, *p*-cymene), 107.0 (ArC, C-b, *p*-cymene), 114.8 (ArCH, C-1), 118.5 (ArCH, C-4), 121.9 (ArCH, C-3), 123.7 (ArCH, C-9), 127.2 (ArCH, C-11), 130.3 (ArC, C-5), 135.9 (ArCH, C-10), 139.4 (ArC, C-7), 150.3 (ArC, C-12), 154.2 (ArC, C-2), 156.4 (ArC, C-6), 161.1 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 588.96 [M-Cl]<sup>+</sup>.

**2-(6-bromopyridin-2-yl)benzo[d]thiazole (3g)**: Yield: 90%, R<sub>f</sub> (25% ethyl acetate in hexane): 0.6; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 7.38 (t, 1H, *J* = 7.6 Hz, ArH), 7.44 (t, 1H, *J* = 8.0 Hz, ArH), 7.50 (d, 1H, *J* = 7.6 Hz, ArH), 7.64 (t, 1H, *J* = 7.6 Hz, ArH), 7.90 (d, 1H, *J* = 8.0 Hz, ArH), 8.03 (d, 1H, *J* = 8.0 Hz, ArH), 8.26 (d, 1H, *J* = 7.6 Hz, ArH); LC-MS (CH<sub>3</sub>OH): *m/z* 290.95 [M+H]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl{2-(6-bromopyridin-2-yl)benzo[d]thiazole}]·Cl (5g)**: 108.55 mg (0.18 mmol, 91 %); *Mr* (C<sub>22</sub>H<sub>21</sub>N<sub>2</sub>SBrCl<sub>2</sub>Ru) = 597.36 g/mol; Anal. calcd for C<sub>22</sub>H<sub>21</sub>N<sub>2</sub>SBrCl<sub>2</sub>Ru (%): C 44.23, H 3.54, N 4.69. Found: C 44.65, H 3.79, N 4.27.; Mp: 230-232°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.30; IR (cm<sup>-1</sup>):  $\nu$  3382, 3046, 2945, 1616, 1514, 1417, 1365, 945, 824, 742; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  (ppm) 1.27 (d, 6H, *J* = 6.0 Hz, *p*-cym CH<sub>3</sub>, H-i, H-j), 2.15 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.88-2.95 (m, 1H, *p*-cym CH, H-h), 5.34 (d, 2H, *J* = 5.6 Hz, *p*-cym ArH, H-e, H-f), 5.48 (d, 2H, *J* = 6.0 Hz, *p*-cym ArH, H-c, H-d), 7.44 (t, 1H, *J* = 7.6 Hz, ArH, H-2), 7.49-7.54 (m, 1H, ArH, H-3), 7.56 (d, 1H, *J* = 8.0 Hz, ArH, H-11), 7.70 (t, *J* = 8.0 Hz, 1H, ArH, H-4), 7.96 (d, 1H, *J* = 8.0 Hz, ArH, H-1), 8.1 (d, 1H, *J* = 7.6 Hz, ArH, H-10), 8.32 (d, 1H, *J* = 8.0 Hz, H-9);

<sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 22.7 (Me, C-i, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 85.1 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.5 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.8 (ArC, C-b, *p*-cymene), 120.3 (ArCH, C-1), 123.2 (ArCH, C-4), 123.9 (ArCH, C-9), 126.6 (ArCH, C-2), 126.8 (ArCH, C-3), 127.4 (ArCH, C-11), 130.8 (ArC, C-5), 135.9 (ArCH, C-10), 141.6 (ArC, C-12), 151.9 (ArC, C-7), 154.1 (ArC, C-6), 167.3 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 561 [M-Cl]<sup>+</sup>

**[(*η*<sup>6</sup>-*p*-cymene)RuCl<sub>2</sub>(2-(6-bromopyridin-2-yl)-5-chlorobenzo[d]thiazole)]Cl (5h):** 88.4 mg (0.14 mmol, 90 %); *Mr* (C<sub>22</sub>H<sub>20</sub>N<sub>2</sub>SBrCl<sub>3</sub>Ru) = 621.80 g/mol; Anal. calcd for C<sub>22</sub>H<sub>20</sub>N<sub>2</sub>SBrCl<sub>3</sub>Ru (%): C 41.82, H 3.19, N 4.43. Found: C 41.59, H 3.49, N 4.18; Mp: 232-234°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.34; IR (cm<sup>-1</sup>): ν 3384, 3044, 2965, 1616, 1592, 1417, 1370, 945, 827, 752; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 1.22 (d, 6H, *J* = 6.8 Hz, *p*-cym CH<sub>3</sub>, H-i, H-j), 2.09 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.82-2.91 (m, 1H, *p*-cym CH, H-h), 5.28 (d, 2H, *J* = 5.6 Hz, *p*-cym ArH, H-e, H-f), 5.41 (d, 2H, *J* = 5.6 Hz, *p*-cym ArH, H-c, H-d), 7.34-7.36 (m, 1H, ArH, H-2), 7.52 (d, 1H, *J* = 8.0 Hz, ArH, H-11), 7.65 (t, 1H, *J* = 7.6 Hz, ArH, H-1), 7.81 (d, 1H, *J* = 8.4 Hz, ArH, H-10), 8.0 (brs, 1H, ArH, H-9), 8.24 (d, 1H, *J* = 7.6 Hz, ArH, H-4); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 22.6 (Me, C-i, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 85.3 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.8 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.8 (ArC, C-b, *p*-cymene), 120.5 (ArCH, C-4), 123.3 (ArCH, C-1), 124.8 (ArCH, C-9), 126.9 (ArCH, C-2), 131.2 (ArCH, C-11), 132.2 (ArC, C-3), 134.7 (ArC, C-5), 141.7 (ArCH, C-10), 143.9 (ArC, C-12), 148.1 (ArC, C-7), 154.9 (ArC, C-6), 158.3 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 594.89 [M-Cl]<sup>+</sup>.

**2-(1H-benzo[d]imidazol-2-yl)quinoline (10a):** Yield: 94%, R<sub>f</sub> (25% ethylacetate in hexane): 0.33; IR (cm<sup>-1</sup>): ν 2158, 1589, 1500, 1442, 1328, 943, 833, 742; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 7.54 (d, 1H, *J* = 8.0 Hz, ArCH<sub>3</sub>), 7.73 (d, 6H, *J* = 8.0 Hz, ArCH<sub>3</sub>), 7.92 (t, 1H, *J* = 6.0 Hz, ArCH<sub>3</sub>), 8.39-8.45 (m, 2H, ArCH<sub>3</sub>), 10.00 (s, 1H, ArNH); ESI-MS (CH<sub>3</sub>OH): *m/z* 246.10 [M+H]<sup>+</sup>.

**[(*η*<sup>6</sup>-*p*-cymene)RuCl<sub>2</sub>(2-(1H-benzo[d]imidazol-2-yl)quinolone)]Cl (11a):**

122.4 mg (0.22 mmol, 96 %); *Mr* (C<sub>26</sub>H<sub>25</sub>N<sub>3</sub>Cl<sub>2</sub>Ru) = 551.47 g/mol; Anal. calcd for C<sub>26</sub>H<sub>25</sub>N<sub>3</sub>Cl<sub>2</sub>Ru (%): C 56.63, H 4.57, N 7.62. Found: C 56.34, H 4.28, N 7.94.; Mp: 228-230°C decomp. ; R<sub>f</sub> (100% ethyl acetate): 0.31; IR (cm<sup>-1</sup>): ν 3441, 3055, 2926, 1593, 1504, 1469, 1425, 1327, 1142, 825, 748; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.68 (d, 3H, *J* = 6.4 Hz, *p*-cymCH<sub>3</sub>, H-j), 0.71 (d, 3H, *J* = 6.8 Hz, *p*-cym CH<sub>3</sub>, H-i), 2.28 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.79-2.85 (m, 1H, *p*-cym CH, H-h), 6.08 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-f), 6.23 (d, 1H, *J* = 6.0 Hz, *p*-cym ArCH), 6.28-6.32 (m, 2H, *p*-cym ArH, H-c, H-d), 7.61-7.63 (m, 2H, Ar H, H-2, H-3), 7.89 (d, 1H, *J* = 6.8 Hz, ArH, H-1), 7.95 (t, 1H, *J* = 7.6 Hz, ArH, H-4), 8.15-8.18 (m, 2H, ArH, H-12, H-13), 8.28 (d, 1H, *J* = 8.0 Hz, ArH, H-9), 8.65 (d, 1H, *J* = 8.4 Hz, ArH, H-14), 8.82 (d, 1H, *J* = 8.8 Hz, Ar H, H-11), 8.96 (d, 1H, *J* = 8.4 Hz, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.9 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 22.1 (Me, C-i, *p*-cymene), 30.7 (CH, C-h, *p*-cymene), 84.1 (ArCH, C-f, *p*-cymene), 85.6 (ArCH, C-e, *p*-cymene), 85.9 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 100.5 (ArC, C-g, *p*-cymene), 106.8 (ArC, C-b, *p*-cymene), 115.1 (ArCH, C-4), 118.4 (ArCH, C-1), 119.2 (ArCH, C-9), 125.6 (ArCH, C-3), 126.6 (ArCH, C-2), 129.3 (ArC, C-15), 129.7 (ArCH, C-12), 129.8 (ArCH, C-11), 130.2 (ArCH, C-14), 130.5 (ArCH, C-13), 133.6 (ArCH, C-10), 138.1 (ArC, C-6), 141.8 (ArC, C-5), 142.5 (ArC, C-7), 148.9 (ArC, C-16), 151.1 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 516.08 [M-Cl]<sup>+</sup>.

**[(*η*<sup>6</sup>-*p*-cymene)RuCl<sub>2</sub>(5-chloro-1H-benzo[d]imidazol-2-yl)quinolone)]Cl (11b):** 51.4 mg (0.088 mmol, 50 %); *Mr* (C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>Cl<sub>3</sub>Ru) = 585.92 g/mol; Anal. calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>Cl<sub>3</sub>Ru (%):

C 53.30, H 4.13, N 7.17. Found: C 53.02, H 4.32, N 7.36.; Mp: 226-228°C decomp; R<sub>f</sub> (100% ethyl acetate): 0.29; IR (cm<sup>-1</sup>): ν 3443, 3105, 2916, 1594, 1504, 1468, 1428, 1326, 1147, 826, 748; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.72 (dd, 6H, J<sub>1</sub> = 6.8 Hz, J<sub>2</sub> = 2.8 Hz, *p*-cymCH<sub>3</sub>, H-i, H-j), 2.29 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 3.24 (brs, 1H, *p*-cym CH, H-h), 5.51 (d, 1H, J = 6.0 Hz, *p*-cym ArH, H-f), 5.61 (d, 1H, J = 6.0 Hz, *p*-cym ArH, H-e), 5.66 (brs, 2H, *p*-cym ArH, H-c, H-d), 7.54 (d, 1H, J = 8.8 Hz, ArH, H-2), 7.61 (t, 1H, J = 8.0 Hz, ArH, H-1), 7.77 (s, 1H, ArH, H-9), 7.81-7.87 (m, 3H, ArH, H-12, H-13, H-14), 8.25 (d, 1H, J = 8.4 Hz, ArH, H-11), 8.39 (d, 1H, J = 8.4 Hz, ArH, H-4), 8.78 (d, 1H, J = 8.8 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.3 (Me, C-a, *p*-cymene), 21.5 (Me, C-j, *p*-cymene), 21.9 (Me, C-i, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 84.2 (ArCH, C-f, *p*-cymene), 85.8 (ArCH, C-e, *p*-cymene), 85.9 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 102.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 117.0 (ArCH, C-4), 119.2 (ArCH, C-1), 119.6 (ArCH, C-9), 120.6 (ArCH, C-2), 128.4 (ArC, C-15), 129.5 (ArCH, C-12), 129.8 (ArCH, C-11), 129.9 (ArCH, C-14), 130.1 (ArC, C-3), 130.9 (ArCH, C-13), 133.7 (ArC, C-5), 141.8 (ArCH, C-10), 141.9 (ArC, C-6), 145.1 (ArC, C-7), 149.0 (ArC, C-16), 154.7 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): m/z 550.00 [M-Cl]<sup>+</sup>.

**[(*η*<sup>6</sup>-*p*-cymene)RuCl{2-(6-chloro-1H-benzo[d]imidazol-2-yl)quinolone}]Cl (11b<sup>+</sup>):** 46.2 mg (0.079 mmol, 45 %); Mr (C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>Cl<sub>3</sub>Ru) = 585.92 g/mol; Anal. calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>Cl<sub>3</sub>Ru (%): C 53.30, H 4.13, N 7.17. Found: C 53.05, H 4.36, N 7.32.; Mp: 227-230°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.26; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.74 (d, 3H, J = 6.8 Hz, *p*-cymCH<sub>3</sub>, H-j), 0.80 (d, 3H, J = 6.8 Hz, *p*-cymCH<sub>3</sub>, H-i), 2.21 (brs, 1H, *p*-cym CH, H-h), 2.29 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 5.41 (d, 1H, J = 5.6 Hz, *p*-cym ArH, H-f), 5.69-5.74 (m, 3H, *p*-cym ArH, H-c, H-d, H-e), 7.38-7.44 (m, 2H, J = ArH, H-3, H-4), 7.64-7.72 (m, 3H, ArH, H-9, H-12, H-13), 7.93 (d, 2H, J = 7.2 Hz, ArH, H-11, H-14), 8.45 (d, 1H, J = 8.4 Hz, ArH, H-1), 8.68-8.70 (m, 1H, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 22.1 (Me, C-i, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 84.1 (ArCH, C-f, *p*-cymene), 85.7 (ArCH, C-e, *p*-cymene), 85.9 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 100.5 (ArC, C-g, *p*-cymene), 106.8 (ArC, C-b, *p*-cymene), 116.8 (ArCH, C-1), 118.1 (ArCH, C-4), 119.5 (ArCH, C-9), 122.5 (ArCH, C-3), 128.4 (ArCH, C-11), 129.4 (ArCH, C-15), 129.7 (ArCH, C-12), 129.9 (ArC, C-14), 130.0 (ArC, C-2), 133.6 (ArC, C-13), 137.8 (ArC, C-6), 141.8 (ArCH, C-10), 141.9 (ArC, C-5), 144.9 (ArC, C-7), 148.9 (ArC, C-16), 152.0 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): m/z 550.00 [M-Cl]<sup>+</sup>.

**[(*η*<sup>6</sup>-*p*-cymene)RuCl{2-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)quinolone}]Cl (11d):** 46.6 mg (0.075 mmol, 53 %); Mr (C<sub>27</sub>H<sub>24</sub>N<sub>3</sub>Cl<sub>2</sub>F<sub>3</sub>Ru) = 619.47 g/mol; Anal. calcd for C<sub>27</sub>H<sub>24</sub>N<sub>3</sub>Cl<sub>2</sub>F<sub>3</sub>Ru (%): C 52.35, H 3.90, N 6.78. Found: C 52.70, H 4.34, N 6.38.; Mp: 230-232°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.23; IR (cm<sup>-1</sup>): ν 3442, 3057, 2921, 1591, 1500, 1469, 1427, 1317, 1142, 1045, 829, 745; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.72 (d, 6H, J = 7.2 Hz, H-i, H-j), 2.26 (brs, 1H, *p*-cym CH, H-h), 2.30 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 5.53 (d, 1H, J = 6.0 Hz, *p*-cym ArH, H-f), 5.61 (d, 1H, J = 6.0 Hz, *p*-cym ArH, H-e), 5.67 (brs, 2H, *p*-cym ArH, H-c, H-d), 7.45 (d, 1H, J = 8.4 Hz, ArH, H-9), 7.63 (d, 1H, J = 7.2 Hz, ArH, H-1), 7.69 (d, 1H, J = 8.4 Hz, ArH, H-2), 7.83-7.89 (m, 2H, ArH, H-12, H-13), 8.09 (s, 1H, ArH, H-4), 8.28 (d, 1H, J = 8.4 Hz, ArH, H-14), 8.43 (d, 1H, J = 8.4 Hz, ArH, H-11), 8.80 (d, 1H, J = 8.8 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 22.3 (Me, C-i, *p*-cymene), 30.5 (CH, C-h, *p*-cymene), 83.9 (ArCH, C-f, *p*-cymene), 85.1 (ArCH, C-e, *p*-cymene), 85.9 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 112.8 (ArCH, C-4), 114.6 (ArCH, C-1), 117.6 (ArCH, C-2), 118.9 (ArC, C-17), 120.3 (ArC, C-3), 127.7 (ArC, C-15), 129.1 (ArCH, C-12), 129.6 (ArCH, C-11), 129.8 (ArCH, C-14), 130.5 (ArCH, C-13), 133.5 (ArCH, C-10), 135.3 (ArC, C-6), 141.6 (ArC, C-7), 148.9 (ArC, C-5), 155.1 (ArC, C-16), 161.9 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): m/z 584.06 [M-Cl]<sup>+</sup>.



**[( $\eta^6$ -*p*-cymene)RuCl<sub>2</sub>(2-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)quinolone)]·Cl (11d<sup>+</sup>):** 36.9 mg (0.059 mmol, 42 %); *Mr* (C<sub>27</sub>H<sub>24</sub>N<sub>3</sub>Cl<sub>2</sub>F<sub>3</sub>Ru) = 619.47 g/mol; Anal. calcd for C<sub>27</sub>H<sub>24</sub>N<sub>3</sub>Cl<sub>2</sub>F<sub>3</sub>Ru (%): C 52.35, H 3.90, N 6.78. Found: C 52.65, H 4.26, N 6.52.; Mp: 226-228°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.21; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.74 (d, 6H, *J* = 6.8 Hz, H-i, H-j), 2.26 (brs, 1H, *p*-cym CH, H-h), 2.30 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 5.55 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-f), 5.61 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-e), 5.68 (d, 2H, *J* = 6.4 Hz, *p*-cym ArH, H-c, H-d), 7.43 (d, 1H, *J* = 8.4 Hz, ArH, H-4), 7.62-7.70 (m, 2H, ArH, H-1, H-3), 7.85-7.89 (m, 3H, ArH, H-9, H-12, H-13), 8.29 (d, 1H, *J* = 8.8 Hz, ArH, H-14), 8.44 (d, 1H, *J* = 8.4 Hz, ArH, H-11), 8.81 (d, 1H, *J* = 8.4 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 19.0 (Me, C-a, *p*-cymene), 21.7 (Me, C-j, *p*-cymene), 22.2 (Me, C-i, *p*-cymene), 30.8 (CH, C-h, *p*-cymene), 84.2 (ArCH, C-f, *p*-cymene), 85.1 (ArCH, C-e, *p*-cymene), 86.0 (ArCH, C-d, *p*-cymene), 86.9 (ArCH, C-c, *p*-cymene), 100.7 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 112.8 (ArCH, C-1), 115.1 (ArCH, C-4), 119.4 (ArCH, C-3), 119.8 (ArC, C-17), 122.1 (ArC, C-2), 125.6 (ArC, C-15), 129.4 (ArCH, C-12), 129.7 (ArCH, C-11), 129.9 (ArCH, C-14), 133.7 (ArCH, C-13), 141.9 (ArCH, C-10), 144.3 (ArC, C-5), 149.1 (ArC, C-7), 156.7 (ArC, C-16), 162.3 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 584.06 [M-Cl]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl<sub>2</sub>(2-(5-methoxy-1H-benzo[d]imidazol-2-yl)quinolone)]·Cl (11e):** 49.5 mg (0.085 mmol, 47 %); *Mr* (C<sub>27</sub>H<sub>27</sub>N<sub>3</sub>OCl<sub>2</sub>Ru) = 581.50 g/mol; Anal. calcd for C<sub>27</sub>H<sub>27</sub>N<sub>3</sub>OCl<sub>2</sub>Ru (%): C 55.77, H 4.68, N 7.23. Found: C 55.39, H 4.31, N 7.58.; Mp: 228-230°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.32; IR (cm<sup>-1</sup>): ν 3451, 3045, 2928, 1596, 1504, 1459, 1415, 1347, 1142, 829, 748; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.76 (d, 6H, *J* = 6.8 Hz, H-i, H-j), 2.11 (brs, 1H, *p*-cym CH, H-h), 2.26 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 3.92 (s, 3H, -OMe, H-17), 5.52 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-f), 5.58 (d, 1H, *J* = 6.4 Hz, *p*-cym ArH, H-e), 5.64 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-d), 5.70 (d, 1H, *J* = 5.2 Hz, *p*-cym ArH, H-c), 7.58 (d, 2H, *J* = 8.0 Hz, ArH, H-2, H-4), 7.69 (d, 1H, *J* = 8.8 Hz, ArH, H-9), 7.78-7.83 (m, 3H, ArH, H-1, H-12, H-13), 8.18 (d, 1H, *J* = 8.4 Hz, ArH, H-14), 8.34 (d, 1H, *J* = 8.4 Hz, ArH, H-11), 8.77 (d, 1H, *J* = 8.4 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 22.3 (Me, C-i, *p*-cymene), 30.9 (CH, C-h, *p*-cymene), 57.4 (OMe, C-17), 85.3 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.5 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 111.2 (ArCH, C-4), 114.8 (ArCH, C-2), 118.5 (ArCH, C-1), 122.5 (ArCH, C-9), 125.5 (ArC, C-15), 126.7 (ArCH, C-12), 129.4 (ArCH, C-11), 133.1 (ArCH, C-14), 135.3 (ArCH, C-13), 141.9 (ArC, C-5), 142.1 (ArCH, C-10), 148.8 (ArC, C-6), 149.5 (ArC, C-7), 150.4 (ArC, C-16), 157.4 (ArC, C-3), 163.7 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 546.09 [M-Cl]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl<sub>2</sub>(2-(6-methoxy-1H-benzo[d]imidazol-2-yl)quinolone)]Cl (11e<sup>+</sup>):** 52.6 mg (0.090 mmol, 50 %); *Mr* (C<sub>27</sub>H<sub>27</sub>N<sub>3</sub>OCl<sub>2</sub>Ru) = 581.50 g/mol, Anal. calcd for C<sub>27</sub>H<sub>27</sub>N<sub>3</sub>OCl<sub>2</sub>Ru (%): C 55.77, H 4.68, N 7.23. Found: C 55.42, H 4.43, N 7.44.; Mp: 229-231°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.35; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.72 (dd, 6H, *J*<sub>1</sub> = 6.8 Hz, *J*<sub>2</sub> = 2.8 Hz, H-i, H-j), 2.04-2.13 (m, 1H, *p*-cym CH, H-h), 2.28 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 3.84 (s, 3H, OMe, H-17), 5.52 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-f), 5.59 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-e), 5.64-5.69 (m, 2H, *p*-cym ArH, H-c, H-d), 7.25 (brs, 1H, ArH, H-1), 7.50-7.58 (m, 2H, ArH, H-3, H-4), 7.69 (d, 1H, *J* = 8.8 Hz, ArH, H-9), 7.78-7.83 (m, 2H, ArH, H-12, H-13), 8.16-8.19 (m, 1H, ArH, H-14), 8.32-8.35 (m, 1H, ArH, H-11), 8.75 (d, 1H, *J* = 8.4 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 22.2 (Me, C-i, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 57.8 (OMe, C-17), 84.1 (ArCH, C-f, *p*-cymene), 85.2 (ArCH, C-e, *p*-cymene), 85.9 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 112.3 (ArCH, C-1), 115.3 (ArCH, C-3), 119.6 (ArCH, C-4), 123.0 (ArC, C-9), 128.4 (ArC, C-15), 129.5 (ArCH, C-12), 129.8 (ArCH, C-11), 130.0 (ArCH, C-14), 133.7 (ArCH, C-13), 141.8 (ArC, C-6), 141.9 (ArC,

C-10), 145.3 (ArC, C-5), 149.0 (ArC, C-7), 154.6 (ArC, C-16), 158.0 (ArCH, C-2), 164.3 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): m/z 546.09 [M-Cl]<sup>+</sup>

**[( $\eta^6$ -*p*-cymene)RuCl{2-(5-nitro-1H-benzo[d]imidazol-2-yl)quinolone}]Cl (11f):** 49.6 mg (0.083 mmol, 51 %); *Mr* (C<sub>26</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>Cl<sub>2</sub>Ru) = 596.47 g/mol; Anal. calcd for C<sub>26</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>Cl<sub>2</sub>Ru (%): C 52.35, H 4.06, N 9.39. Found: C 52.66, H 4.38, N 9.58.; Mp: 237-240°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.21; IR (cm<sup>-1</sup>):  $\nu$  3448, 3052 2916, 1594, 1505, 1467, 1424, 1329, 1141, 827, 748; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 0.74 (dd, 6H, *J*<sub>1</sub> = 6.8 Hz, *J*<sub>2</sub> = 2.8 Hz, H-i, H-j), 2.05-2.11 (m, 1H, *p*-cym CH, H-h), 2.33 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 5.53 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-f), 5.62 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-e), 5.66 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-d), 5.68 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-c), 7.62-7.69 (m, 2H, ArH, H-1, H-9), 7.85-7.92 (m, 2H, ArH, H-12, H-13), 8.17 (d, 1H, *J* = 10.8 Hz, ArH, H-14), 8.33 (d, 1H, *J* = 8.4 Hz, ArH, H-2), 8.45 (d, 1H, *J* = 8.0 Hz, ArH, H-4), 8.74 (brs, 1H, ArH, H-11), 8.81 (d, 1H, *J* = 8.4 Hz, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  18.8 (Me, C-a, *p*-cymene), 21.5 (Me, C-j, *p*-cymene), 22.2 (Me, C-i, *p*-cymene), 30.7 (CH, C-h, *p*-cymene), 84.4 (ArCH, C-f, *p*-cymene), 85.7 (ArCH, C-e, *p*-cymene), 85.9 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 100.7 (ArC, C-g, *p*-cymene), 106.8 (ArC, C-b, *p*-cymene), 113.6 (ArCH, C-4), 117.6 (ArCH, C-1), 119.7 (ArCH, C-2), 122.8 (ArCH, C-9), 126.6 (ArC, C-15), 129.3 (ArCH, C-12), 129.5 (ArCH, C-11), 129.7 (ArCH, C-14), 129.8 (ArCH, C-13), 133.4 (ArCH, C-10), 136.9 (ArC, C-6), 141.6 (ArC, C-7), 144.3 (ArC, C-3), 148.9 (ArC, C-5), 154.3 (ArC, C-16), 164.9 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): m/z 561.06 [M-Cl]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl{2-(6-nitro-1H-benzo[d]imidazol-2-yl)quinolone}]Cl (11f')**: 41.9 mg (0.070 mmol, 43 %); *Mr* (C<sub>26</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>Cl<sub>2</sub>Ru) = 596.47 g/mol; Anal. calcd for C<sub>26</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>Cl<sub>2</sub>Ru (%): C 52.35, H 4.06, N 9.39. Found: C 52.61, H 4.32, N 9.52.; Mp: 234-238°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.17; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 0.74 (d, 6H, *J* = 6.8 Hz, H-i, H-j), 2.09-2.13 (m, 1H, *p*-cym CH, H-h), 2.36 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 5.62 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-f), 5.65 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-e), 5.71 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-d), 5.79 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-c), 7.65-7.69 (m, 1H, ArH, H-4), 7.81 (d, 1H, *J* = 9.2 Hz, ArH, H-14), 7.87-7.92 (m, 2H, H-12, H-13), 8.13 (d, 1H, *J* = 11.2 Hz, ArH, H-3), 8.33 (d, 1H, *J* = 8.4 Hz, ArH, H-9), 8.45 (d, 1H, *J* = 8.4 Hz, ArH, H-11), 8.58 (brs, 1H, ArH, H-1), 8.81 (d, 1H, *J* = 8.4 Hz, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  18.9 (Me, C-a, *p*-cymene), 21.6 (Me, C-j, *p*-cymene), 22.3 (Me, C-i, *p*-cymene), 30.8 (CH, C-h, *p*-cymene), 84.5 (ArCH, C-f, *p*-cymene), 85.8 (ArCH, C-e, *p*-cymene), 86.1 (ArCH, C-d, *p*-cymene), 86.9 (ArCH, C-c, *p*-cymene), 100.7 (ArC, C-g, *p*-cymene), 106.8 (ArC, C-b, *p*-cymene), 113.7 (ArCH, C-1), 117.6 (ArCH, C-4), 119.8 (ArCH, C-3), 122.9 (ArCH, C-9), 126.7 (ArC, C-15), 129.4 (ArCH, C-12), 129.6 (ArCH, C-11), 129.8 (ArCH, C-14), 129.9 (ArCH, C-13), 133.5 (ArCH, C-10), 138.8 (ArC, C-5), 141.7 (ArC, C-7), 144.4 (ArC, C-2), 149.1 (ArC, C-6), 154.3 (ArC, C-16), 165.0 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): m/z 561.06 [M-Cl]<sup>+</sup>.

**5-chloro-2-(quinolin-2-yl)benzo[d]thiazole (10h):** Yield: 94%, R<sub>f</sub> (25% ethyl acetate in Hexane): 0.35; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 7.42 (d, *J* = 8.4 Hz, 1H, ArH), 7.60-7.64 (m, 1H, ArCH), 7.76-7.80 (m, 1H, ArH), 7.88 (t, *J* = 8 Hz, 2H, ArH), 8.11 (s, 1H, ArH), 8.19 (d, *J* = 8 Hz, 1H, ArH), 8.32 (d, *J* = 8.4 Hz, 1H, ArH), 8.47 (d, *J* = 8.4 Hz, 1H, ArH); ESI-MS (CH<sub>3</sub>OH): m/z 297.02 [M+H]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl{5-chloro-2-(quinolin-2-yl)benzo[d]thiazole}]Cl (11h):** 88.7 mg (0.147 mmol, 94 %); *Mr* (C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>SCl<sub>3</sub>Ru) = 602.97 g/mol; Anal. calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>SCl<sub>3</sub>Ru (%): C 51.79, H 3.84, N 4.65. Found: C 52.18, H 4.36, N 4.88.; Mp: 222-224°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.25; IR (cm<sup>-1</sup>):  $\nu$  3381, 3051, 2924, 1614, 1591, 1516, 1425, 1371, 1095, 925, 827, 763; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  (ppm) 0.74 (d, 3H, *J* = 6.8 Hz, H-j), 0.81 (d, 3H, *J* =

6.8 Hz, H-i), 2.28 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.79-2.85 (m, 1H, *p*-cym CH, H-h), 6.08 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-f), 6.29-6.33 (m, 3H, *p*-cym ArH, H-c, H-d, H-e), 7.93 (d, 1H, *J* = 8.8 Hz, ArH, H-2), 8.01 (t, 1H, *J* = 7.2 Hz, ArH, H-12), 8.19 (t, 1H, *J* = 8.0 Hz, ArH, H-13), 8.35 (brs, 2H, ArH, H-1, H-9), 8.59 (d, 1H, *J* = 8.8 Hz, ArH, H-14), 8.71 (d, 1H, *J* = 8.0 Hz, ArH, H-11), 8.81 (d, 1H, *J* = 8.8 Hz, H-4), 8.98 (d, 1H, *J* = 8.4 Hz, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.6 (Me, C-a, *p*-cymene), 21.4 (Me, C-j, *p*-cymene), 22.3 (Me, C-i, *p*-cymene), 30.7 (CH, C-h, *p*-cymene), 82.1 (ArCH, C-f, *p*-cymene), 84.3 (ArCH, C-e, *p*-cymene), 85.6 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 104.9 (ArC, C-b, *p*-cymene), 121.6 (ArCH, C-1), 122.1 (ArCH, C-4), 127.1 (ArCH, C-2), 129.6 (ArCH, C-9), 126.8 (ArC, C-15), 129.9 (ArCH, C-12), 130.9 (ArCH, C-11), 132.9 (ArC, C-3), 134.2 (ArCH, C-14), 134.8 (ArCH, C-13), 142.3 (ArCH, C-10), 149.3 (ArC, C-6), 151.4 (ArC, C-16), 151.8 (ArC, C-5), 161.6 (ArC, C-7), 168.0 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 567.00 [M-Cl]<sup>+</sup>

**[(*η*<sup>6</sup>-*p*-cymene)RuCl{2-(5,6-dimethyl-1H-benzo[d]imidazol-2-yl)quinolone}]Cl (11i):** 103.2 mg (0.178 mmol, 97 %); *Mr* (C<sub>28</sub>H<sub>29</sub>N<sub>3</sub>Cl<sub>2</sub>Ru) = 579.52 g/mol; Anal. calcd for C<sub>28</sub>H<sub>29</sub>N<sub>3</sub>Cl<sub>2</sub>Ru (%): C 58.03, H 5.04, N 7.25. Found: C 58.38, H 5.32, N 7.48.; Mp: 234-236°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.33; IR (cm<sup>-1</sup>): ν 3446, 3052, 2928, 1598, 1500, 1462, 1429, 1333, 1157, 828, 756; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.80 (d, 6H, *J* = 6.8 Hz, *p*-cym CH<sub>3</sub>, H-i, H-j), 2.11 (brs, 1H, *p*-cym CH, H-h), 2.30 (s, 6H, *p*-cym CH<sub>3</sub>, H-a), 2.36 (s, 3H, Me, H-18), 2.42 (s, 3H, Me, H-17), 5.51 (d, 1H, *J* = 5.2 Hz, *p*-cym ArH, H-f), 5.60 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-e), 5.68 (brs, 2H, *p*-cym ArH, H-c, H-d), 7.38 (s, 1H, ArH, H-9), 7.56 (brs, 2H, ArH, H-1, H-4), 7.77-7.83 (m, 2H, ArH, H-12, H-13), 8.17 (d, 1H, *J* = 8.0 Hz, ArH, H-14), 8.36 (d, 1H, *J* = 8.0 Hz, ArH, H-11), 8.77 (d, 1H, *J* = 8.8 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 14.6 (Me, C-18), 15.6 (Me, C-17), 18.9 (Me, C-a, *p*-cymene), 21.6 (Me, C-j, *p*-cymene), 22.2 (Me, C-i, *p*-cymene), 31.1 (CH, C-h, *p*-cymene), 85.2 (ArCH, C-f, *p*-cymene), 85.8 (ArCH, C-e, *p*-cymene), 87.2 (ArCH, C-d, *p*-cymene), 87.4 (ArCH, C-c, *p*-cymene), 105.4 (ArC, C-g, *p*-cymene), 105.6 (ArC, C-b, *p*-cymene), 117.6 (ArCH, C-4), 119.9 (ArCH, C-1), 124.8 (ArCH, C-9), 125.6 (ArC, C-15), 126.6 (ArCH, C-12), 129.3 (ArCH, C-11), 129.7 (ArCH, C-14), 129.8 (ArCH, C-13), 130.8 (ArC, C-3), 133.9 (ArC, C-2), 140.1 (ArC, C-6), 141.5 (ArC, C-5), 147.6 (ArCH, C-10), 148.8 (ArC, C-7), 156.1 (ArC, C-16), 171.9 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 544.11 [M-Cl]<sup>+</sup>.

**[(*η*<sup>6</sup>-*p*-cymene)RuCl{2-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)quinolone}]Cl (11j):** 83.2 mg (0.134 mmol, 95 %); *Mr* (C<sub>26</sub>H<sub>23</sub>N<sub>3</sub>Cl<sub>4</sub>Ru) = 620.36 g/mol; Anal. calcd for C<sub>26</sub>H<sub>23</sub>N<sub>3</sub>Cl<sub>4</sub>Ru (%): C 50.34, H 3.74, N 6.77. Found: C 50.73, H 3.45, N 7.14.; Mp: 232-234°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.28; IR (cm<sup>-1</sup>): ν 3445, 3058, 2934, 1599, 1501, 1479, 1421, 1326, 1140, 815, 746; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 0.63 (d, 3H, *J* = 6.8 Hz, *p*-cymCH<sub>3</sub>, H-j), 0.73 (d, 3H, *J* = 6.8 Hz, *p*-cymCH<sub>3</sub>, H-i), 2.29 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.79-2.85 (m, 1H, *p*-cym CH, H-h), 6.07 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-f), 6.29 (d, 2H, *J* = 6.0 Hz, *p*-cym ArH, H-d, H-e), 6.40 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-c), 7.96 (t, 1H, *J* = 7.2 Hz, ArH, H-9), 8.16-8.19 (m, 2H, ArH, H-13, H-12), 8.28 (d, 1H, *J* = 8.0 Hz, ArH, H-14), 8.33 (s, 1H, ArH, H-11), 8.68 (d, 1H, *J* = 8.4 Hz, ArH, H-1), 8.81 (d, 1H, *J* = 8.8 Hz, ArH, H-4), 8.97 (d, 1H, *J* = 8.4 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>): δ 18.9 (Me, C-a, *p*-cymene), 21.5 (Me, C-j, *p*-cymene), 22.3 (Me, C-i, *p*-cymene), 30.6 (CH, C-h, *p*-cymene), 83.7 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.1 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 102.8 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 116.7 (ArCH, C-1), 119.3 (ArCH, C-4), 119.6 (ArCH, C-9), 128.4 (ArC, C-15), 129.0 (ArCH, C-12), 129.5 (ArCH, C-11), 129.7 (ArC, C-3), 129.8 (ArC, C-2), 130.1 (ArCH, C-14), 133.8 (ArCH, C-13), 135.6 (ArCH, C-10), 141.8 (ArC, C-6), 141.9 (ArC, C-5), 148.2 (ArC, C-7), 149.0 (ArC, C-16), 153.5 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 584.00 [M-Cl]<sup>+</sup>.

**( $\eta^6$ -*p*-cymene)RuCl{2-(5-fluoro-1H-benzo[d]imidazol-2-yl)quinolone}Cl (11k):** 55.31 mg (0.097 mmol, 49 %); *Mr* (C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>FCl<sub>2</sub>Ru) = 569.46 g/mol; Anal. calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>FCl<sub>2</sub>Ru (%): C 54.84, H 4.25, N 7.38. Found: C 54.36, H 4.59, N 7.73.; Mp: 234-236°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.25; IR (cm<sup>-1</sup>):  $\nu$  3445, 3055, 2929, 1587, 1509, 1459, 1425, 1410, 1327, 1142, 1065, 827, 748; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 0.73 (d, 3H, *J* = 2.8 Hz, *p*-cymCH<sub>3</sub>, H-j), 0.78 (d, 3H, *J* = 2.8 Hz, *p*-cymCH<sub>3</sub>, H-i), 2.21 (brs, 1H, *p*-cym CH, H-h), 2.27 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 5.62 (brs, 1H, *p*-cym ArH, H-f), 5.73 (brs, 3H, *p*-cym ArH, H-c, H-d, H-e), 7.33-7.41 (m, 2H, *J* = ArH, H-2, H-4), 7.64-7.70 (m, 3H, ArH, H-1, H-12, H-13), 7.88 (d, 2H, *J* = 8.0 Hz, ArH, H-9, H-14), 8.41 (d, 1H, *J* = 8.4 Hz, ArH, H-11), 9.23 (d, 1H, *J* = 8.0 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 22.2 (Me, C-i, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 84.1 (ArCH, C-f, *p*-cymene), 85.7 (ArCH, C-e, *p*-cymene), 85.9 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 116.9 (ArCH, C-2), 119.3 (ArCH, C-1), 122.6 (ArCH, C-4), 129.3 (ArCH, C-9), 129.4 (ArC, C-15), 129.7 (ArCH, C-12), 129.8 (ArCH, C-11), 129.9 (ArCH, C-14), 133.7 (ArCH, C-13), 139.2 (ArC, C-5), 141.9 (ArCH, C-10), 148.4 (ArC, C-6), 148.9 (ArC, C-7), 152.3 (ArC, C-16), 159.9 (ArC, C-3), 162.4 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 534.10 [M-Cl]<sup>+</sup>.

**( $\eta^6$ -*p*-cymene)RuCl{2-(6-fluoro-1H-benzo[d]imidazol-2-yl)quinolone}Cl (11k')**: 53.1 mg (0.093 mmol, 47 %); *Mr* (C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>FCl<sub>2</sub>Ru) = 569.46 g/mol; Anal. calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>FCl<sub>2</sub>Ru (%): C 54.84, H 4.25, N 7.38. Found: C 54.51, H 4.52, N 7.66.; Mp: 234-236°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.23; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 0.73 (brs, 3H, *p*-cymCH<sub>3</sub>, H-j), 0.78 (brs, 3H, *p*-cymCH<sub>3</sub>, H-i), 2.27 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.83 (sept, 1H, *J* = 6.8 Hz, *p*-cym CH, H-h), 5.62 (brs, 1H, *p*-cym ArH, H-f), 5.73-5.81 (m, 3H, *p*-cym ArH, H-c, H-d, H-e), 7.32-7.41 (m, 2H, *J* = ArH, H-1, H-3), 7.64-7.73 (m, 3H, ArH, H-4, H-9, H-12), 7.88 (d, 2H, *J* = 8.0 Hz, ArH, H-13, H-14), 8.41 (d, 1H, *J* = 8.4 Hz, ArH, H-11), 9.23 (d, 1H, *J* = 8.0 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  18.4 (Me, C-a, *p*-cymene), 21.7 (Me, C-j, *p*-cymene), 22.2 (Me, C-i, *p*-cymene), 30.5 (CH, C-h, *p*-cymene), 84.1 (ArCH, C-f, *p*-cymene), 85.7 (ArCH, C-e, *p*-cymene), 86.0 (ArCH, C-d, *p*-cymene), 86.9 (ArCH, C-c, *p*-cymene), 100.7 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 116.8 (ArCH, C-1), 119.3 (ArCH, C-3), 122.4 (ArCH, C-4), 129.3 (ArCH, C-9), 129.4 (ArC, C-15), 129.7 (ArCH, C-12), 129.8 (ArCH, C-11), 129.9 (ArCH, C-14), 133.8 (ArCH, C-13), 139.2 (ArC, C-6), 141.9 (ArCH, C-10), 148.4 (ArC, C-5), 149.0 (ArC, C-7), 152.5 (ArC, C-16), 160.0 (ArC, C-2), 162.5 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 534.10 [M-Cl]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl{2-(5-bromo-1H-benzo[d]imidazol-2-yl)quinolone}Cl (11l):** 40.4 mg (0.064 mmol, 48 %); *Mr* (C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>BrCl<sub>2</sub>Ru) = 630.37 g/mol; Anal. calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>BrCl<sub>2</sub>Ru (%): C 49.54, H 3.84, N 6.67. Found: C 49.21, H 4.26, N 6.23.; Mp: 232-234°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.27; IR (cm<sup>-1</sup>):  $\nu$  3444, 3045, 2927, 1591, 1506, 1467, 1416, 1325, 1144, 827, 746; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 0.71 (d, 3H, *J* = 7.6 Hz, *p*-cymCH<sub>3</sub>, H-j), 0.72 (d, 3H, *J* = 7.6 Hz, *p*-cymCH<sub>3</sub>, H-i), 2.21-2.26 (m, 1H, *p*-cym CH, H-h), 2.30 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 5.51 (d, 1H, *J* = 5.6 Hz, *p*-cym ArH, H-f), 5.60 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-e), 5.66 (brs, 2H, *p*-cym ArH, H-c, H-d), 7.32 (d, 1H, *J* = 8.0 Hz, ArH, H-2), 7.50 (d, 1H, *J* = 8.8 Hz, ArH, H-1), 7.62 (t, 1H, *J* = 7.2 Hz, ArH, H-9), 7.83-7.88 (m, 2H, ArH, H-12, H-13), 7.94 (s, 1H, ArH, H-4), 8.25 (d, 1H, *J* = 8.4 Hz, ArH, H-14), 8.39 (d, 1H, *J* = 8.8 Hz, ArH, H-11), 8.78 (d, 1H, *J* = 8.4 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  18.9 (Me, C-a, *p*-cymene), 21.6 (Me, C-j, *p*-cymene), 22.1 (Me, C-i, *p*-cymene), 30.7 (CH, C-h, *p*-cymene), 83.5 (ArCH, C-f, *p*-cymene), 84.8 (ArCH, C-e, *p*-cymene), 85.9 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 100.5 (ArC, C-g, *p*-cymene), 106.8 (ArC, C-b, *p*-cymene), 113.9 (ArCH, C-1), 116.1 (ArCH, C-4), 119.8 (ArC, C-3), 120.1 (ArCH, C-9), 128.3 (ArC, C-15), 129.3 (ArCH, C-2), 129.7 (ArCH, C-12), 129.8 (ArC, C-11), 130.3 (ArCH, C-14), 133.6 (ArCH, C-13), 136.2 (ArCH,

C-10), 141.8 (ArC, C-5), 141.9 (ArC, C-6), 143.9 (ArC, C-7), 148.9 (ArC, C-16), 163.8 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): m/z 593.99 [M-Cl]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl<sub>2</sub>{2-(6-bromo-1H-benzo[d]imidazol-2-yl)quinolone}]Cl (11l')**: 39.6 mg (0.063 mmol, 47 %); *Mr* (C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>BrCl<sub>2</sub>Ru) = 630.37 g/mol; Anal. calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>BrCl<sub>2</sub>Ru (%): C 49.54, H 3.84, N 6.67. Found: C 49.30, H 4.12, N 6.43.; Mp: 231-232°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.24; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 0.72 (d, 6H, *J* = 6.8 Hz, H-I, H-j), 2.02-2.09 (m, 1H, *p*-cym CH, H-h), 2.33 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 5.52 (d, 1H, *J* = 4.0 Hz, *p*-cym ArH, H-f), 5.62 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-e), 5.67 (d, 1H, *J* = 9.4 Hz, *p*-cym ArH, H-d), 5.69 (brs, 1H, *p*-cym ArH, H-c), 7.30 (t, 1H, *J* = 8.8 Hz, ArH, H-3), 7.61 (d, 1H, *J* = 7.2 Hz, ArH, H-4), 7.67 (d, 1H, *J* = 9.2 Hz, ArH, H-9), 7.81-7.87 (m, 2H, ArH, H-12, H-13), 7.94 (s, 1H, ArH, H-1), 8.25 (d, 1H, *J* = 8.4 Hz, ArH, H-14), 8.39 (d, 1H, *J* = 8.4 Hz, ArH, H-11), 8.79 (d, 1H, *J* = 8.8 Hz, ArH, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  19.0 (Me, C-a, *p*-cymene), 21.7 (Me, C-j, *p*-cymene), 22.2 (Me, C-i, *p*-cymene), 30.8 (CH, C-h, *p*-cymene), 84.1 (ArCH, C-f, *p*-cymene), 84.9 (ArCH, C-e, *p*-cymene), 86.1 (ArCH, C-d, *p*-cymene), 86.9 (ArCH, C-c, *p*-cymene), 100.8 (ArC, C-g, *p*-cymene), 107.2 (ArC, C-b, *p*-cymene), 113.9 (ArCH, C-4), 117.7 (ArCH, C-1), 119.9 (ArC, C-2), 120.0 (ArCH, C-9), 120.2 (ArC, C-15), 129.4 (ArCH, C-3), 129.8 (ArCH, C-12), 129.9 (ArCH, C-11), 130.4 (ArCH, C-14), 137.8 (ArCH, C-13), 141.9 (ArCH, C-10), 142.0 (ArC, C-6), 144.0 (ArC, C-5), 149.1 (ArC, C-7), 152.8 (ArC, C-16), 164.0 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): m/z 593.99 [M-Cl]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl<sub>2</sub>{2-(quinolin-2-yl)benzo[d]oxazole}]Cl (11m)**: 121.5 mg (0.219 mmol, 96 %); *Mr* (C<sub>26</sub>H<sub>24</sub>N<sub>2</sub>OCl<sub>2</sub>Ru) = 552.46 g/mol; Anal. calcd for C<sub>26</sub>H<sub>24</sub>N<sub>2</sub>OCl<sub>2</sub>Ru (%): C 56.53, H 4.38, N 5.07. Found: C 56.85, H 4.56, N 5.39.; Mp: 224-226°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.30; IR (cm<sup>-1</sup>):  $\nu$  3351, 3054, 2927, 1600, 1592, 1526, 1427, 1375, 925, 827, 763; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  (ppm) 0.76 (d, 3H, *J* = 6.8 Hz, H-j), 0.89 (d, 3H, *J* = 6.8 Hz, H-i), 2.18 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.28-2.35 (m, 1H, *p*-cym CH, H-h), 5.17 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-f), 5.74 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-e), 5.90 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-d), 6.09 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-c), 7.38 (t, 1H, *J* = 7.6 Hz, ArH, H-4), 7.81 (d, 1H, *J* = 8.0 Hz, ArH, H-1, H-9), 8.02 (t, 1H, *J* = 7.2 Hz, ArH, H-12), 8.18 (t, 1H, *J* = 8.0 Hz, ArH, H-3), 8.31 (d, 1H, *J* = 8.0 Hz, ArH, H-2), 8.39 (d, 1H, *J* = 8.0 Hz, ArH, H-13), 8.74 (d, 1H, *J* = 8.4 Hz, H-14), 8.92 (d, 1H, *J* = 8.0 Hz, H-11), 9.18 (s, 1H, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  18.9 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 22.1 (Me, C-i, *p*-cymene), 30.7 (CH, C-h, *p*-cymene), 83.8 (ArCH, C-f, *p*-cymene), 84.9 (ArCH, C-e, *p*-cymene), 85.9 (ArCH, C-d, *p*-cymene), 86.8 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 116.9 (ArCH, C-1), 117.8 (ArCH, C-4), 119.3 (ArCH, C-9), 122.8 (ArCH, C-2), 123.6 (ArCH, C-3), 127.5 (ArC, C-15), 128.6 (ArCH, C-12), 129.4 (ArCH, C-11), 129.6 (ArCH, C-14), 129.8 (ArCH, C-13), 133.6 (ArCH, C-10), 141.7 (ArC, C-6), 145.9 (ArC, C-16), 148.9 (ArC, C-5), 151.2 (ArC, C-7), 161.2 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): m/z m/z 517.06 [M-Cl]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl<sub>2</sub>{5-bromo-2-(quinolin-2-yl)benzo[d]oxazole}]Cl (11n)**: 79.7 mg (0.126 mmol, 95 %); *Mr* (C<sub>26</sub>H<sub>24</sub>N<sub>2</sub>OCl<sub>2</sub>Ru) = 631.35 g/mol; Anal. calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>OBrCl<sub>2</sub>Ru (%): C 49.46, H 3.67, N 4.44. Found: C 49.68, H 3.91, N 4.81.; Mp: 226-228°C decomp.; R<sub>f</sub> (100% ethyl acetate): 0.24; IR (cm<sup>-1</sup>):  $\nu$  3354, 3057, 2928, 1611, 1594, 1516, 1425, 1368, 925, 827, 753; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  (ppm) 0.82 (d, 3H, *J* = 6.8 Hz, H-j), 0.89 (d, 3H, *J* = 6.8 Hz, H-i), 2.09 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.29-2.37 (m, 1H, *p*-cym CH, H-h), 5.76 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-f), 5.80 (d, 2H, *J* = 5.2 Hz, *p*-cym ArH, H-d, H-e), 5.88 (d, 1H, *J* = 6.0 Hz, *p*-cym ArH, H-c), 7.55 (d, 1H, *J* = 8.8 Hz, ArH, H-4), 7.98 (s, 1H, ArH, H-2), 8.03 (t, 1H, *J* = 7.6 Hz, ArH, H-9), 8.18 (t, 1H, *J* = 7.6 Hz, ArH, H-1), 8.31 (d, 1H, *J* = 8.0 Hz, ArH, H-12), 8.41 (d, 1H, *J* = 8.0 Hz, ArH, H-13), 8.73 (d, 1H, *J* = 8.8 Hz, H-14), 8.93 (d, 1H, *J* = 8.0 Hz, H-11), 9.19 (s, 1H, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sup>6</sup>):  $\delta$  18.7 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-

cymene), 22.1 (Me, C-i, *p*-cymene), 30.4 (CH, C-h, *p*-cymene), 84.9 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.3 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 110.3 (ArCH, C-1), 119.7 (ArCH, C-9), 120.8 (ArCH, C-3), 123.6 (ArCH, C-4), 125.0 (ArCH, C-15), 127.8 (ArCH, C-12), 129.8 (ArCH, C-2), 131.0 (ArCH, C-11), 133.3 (ArC, C-14), 135.0 (ArCH, C-13), 149.1 (ArC, C-10), 147.2 (ArC, C-6), 148.9 (ArC, C-16), 155.8 (ArC, C-5), 170.8 (ArC, C-7), 172.8 (ArC, C-8); ESI-MS (CH<sub>3</sub>OH): *m/z* 594.97 [M-Cl]<sup>+</sup>.

**Characterization data for some Suzuki coupled ligand [7(g1-g3, la-l9)] and their corresponding ruthenium(II)-*p*-cymene complexes [8(g1-g3, la-l9)]**

**2-(6-(4-methoxyphenyl)pyridin-2-yl)benzo[d]thiazole (7g1):** Yield: 95%, *R<sub>f</sub>* (16.5% ethyl acetate in hexane): 0.37; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 3.89 (s, 3H, OCH<sub>3</sub>), 7.05 (d, *J* = 8 Hz, 2H, ArCH), 7.42 (t, 1H, *J* = 8 Hz, ArCH), 7.51 (t, 1H, *J* = 8 Hz, ArCH), 7.77 (d, 1H, *J* = 8 Hz, ArCH), 7.86 (t, 1H, *J* = 8 Hz, ArCH), 7.96 (d, 1H, *J* = 8 Hz, ArCH), 8.11 (t, 3H, *J* = 8 Hz, ArCH), 8.23 (d, 1H, *J* = 8 Hz, ArCH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 55.4 (OCH<sub>3</sub>), 114.2, 118.1, 120.8, 121.9, 123.5, 125.5, 126.1, 128.2, 130.8, 132.1, 136.4, 137.7, 150.9, 154.4, 156.7, 160.9, 170.4; LC-MS (CH<sub>3</sub>OH): *m/z* 319.08 [M+H]<sup>+</sup>.

**[(η<sup>6</sup>-*p*-cymene)RuCl<sub>2</sub>(2-(6-(4-methoxyphenyl)pyridin-2-yl)benzo[d]thiazole)]PF<sub>6</sub> (8g1):** 54.7 mg (0.075 mmol, 95 %); *Mr* (C<sub>29</sub>H<sub>28</sub>N<sub>2</sub>OPSClF<sub>6</sub>Ru) = 734.10 g/mol; Anal. calcd for C<sub>29</sub>H<sub>28</sub>N<sub>2</sub>OPSClF<sub>6</sub>Ru (%): C 47.45, H 3.84, N 3.82 Found: C 47.78, H 3.57, N 4.18.; Mp: 240-242°C decomp.; *R<sub>f</sub>* (100% ethyl acetate): 0.28; IR (cm<sup>-1</sup>): ν 3051, 2941, 1697, 1600, 1554, 1406, 1327, 1176, 1072, 929, 829, 744; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ (ppm) 0.63-0.69 (m, 6H, H-i, H-j), 2.13 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.78-2.85 (m, 1H, *p*-cym CH, H-h), 3.93 (s, 3H, -OMe, H-19), 5.75 (d, 1H, *J* = 6.4 Hz, *p*-cym ArH, H-f), 5.80 (d, 1H, *J* = 6.4 Hz, *p*-cym ArH, H-e), 6.06 (brs, 2H, *p*-cym ArH, H-c, H-d), 7.26 (d, 2H, *J* = 8.8 Hz, H-15, H-16), 7.83 (t, 1H, *J* = 7.2 Hz, ArH, H-2), 7.89 (t, 1H, *J* = 7.2 Hz, ArH, H-3), 7.96 (d, 1H, *J* = 7.2 Hz, ArH, H-9), 8.09-8.11 (m, 2H, ArH, H-4, H-10), 8.29 (d, 1H, *J* = 8.0 Hz, ArH, H-11), 8.38 (t, 1H, *J* = 7.6 Hz, ArH, H-18), 8.48 (d, 1H, *J* = 7.6 Hz, H-14), 8.65 (d, 1H, *J* = 7.6 Hz, H-1); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 100 MHz): δ 18.6 (Me, C-a, *p*-cymene), 21.7 (Me, C-j, *p*-cymene), 24.4 (Me, C-i, *p*-cymene), 31.1 (CH, C-h, *p*-cymene), 56.1 (OMe, C-19), 85.4 (ArCH, C-f, *p*-cymene), 86.0 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 86.9 (ArCH, C-c, *p*-cymene), 102.4 (ArC, C-g, *p*-cymene), 105.4 (ArC, C-b, *p*-cymene), 114.8 (ArCH, C-15), 118.5 (ArCH, C-17), 121.9 (ArCH, C-9), 123.1 (ArCH, C-11), 123.6 (ArCH, C-4), 123.6 (ArCH, C-2), 124.9 (ArCH, C-1), 126.5 (ArCH, C-3), 128.5 (ArC, C-13), 130.3 (ArCH, C-14), 133.1 (ArCH, C-18), 135.9 (ArCH, C-10), 141.1 (ArC, C-7), 150.3 (ArC, C-6), 154.2 (ArC, C-8), 156.4 (ArC, C-12), 161.1 (ArC, C-16); <sup>31</sup>P NMR (162 MHz, DMSO-*d*<sub>6</sub>): δ(ppm) (-153.01)-(-135.45) (m, 1P, PF<sub>6</sub>); <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>): δ(ppm) = -71.02, -69.13 (6F, PF<sub>6</sub>); ESI-MS (CH<sub>3</sub>OH): *m/z* 589.06 [M-Cl]<sup>+</sup>.

**2-(6-(4-formylphenyl)pyridin-2-yl)benzo[d]thiazole (7g2):** Yield: 95%, *R<sub>f</sub>* (16.5% ethyl acetate in hexane): 0.31; IR (cm<sup>-1</sup>): ν 3350, 3049, 2850, 1687, 1674, 1587, 1562, 1506, 1427, 1315, 1211, 1149, 1078, 989, 796, 752; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 7.45 (d, 1H, *J* = 8 Hz, ArCH), 7.52 (t, 1H, *J* = 8 Hz, ArCH), 7.91-7.99 (m, 3H, ArCH), 8.04 (d, 2H, *J* = 8 Hz, ArCH), 8.11 (d, 1H, *J* = 8 Hz, ArCH), 8.32-8.38 (m, 3H, ArCH), 10.11 (s, 1H, ArCHO); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 119.34, 122.03, 122.28, 123.69, 125.81, 126.35, 127.50, 130.25, 136.32, 136.75, 138.15, 143.69, 151.49, 154.36, 155.44, 169.56, 191.97 (CHO); ESI-MS (CH<sub>3</sub>OH): *m/z* 317.09 [M+H]<sup>+</sup>.

**[(η<sup>6</sup>-*p*-cymene)RuCl<sub>2</sub>(2-(6-(4-formylphenyl)pyridin-2-yl)benzo[d]thiazole)]PF<sub>6</sub> (8g2):** 53.8 mg (0.073 mmol, 93 %); *Mr* (C<sub>29</sub>H<sub>26</sub>N<sub>2</sub>OPSClF<sub>6</sub>Ru) = 732.08 g/mol; Anal. calcd for

$C_{29}H_{26}N_2OPSClF_6Ru$  (%): C 47.58, H 3.58, N 3.83 Found: C 47.79, H 3.89, N 4.18.; Mp: 241-243°C decomp.;  $R_f$  (100% ethyl acetate): 0.23; IR ( $cm^{-1}$ ):  $\nu$  3124, 3045, 2835, 1695, 1600, 1564, 1404, 1330, 1182, 831, 761;  $^1H$  NMR (400 MHz, DMSO):  $\delta$ (ppm) Solubility problem;  $^{31}P$  NMR (162 MHz,  $CDCl_3$ ):  $\delta$ (ppm) = (-153.26)-(-135.66) (m, 1P,  $PF_6$ ).  $^{19}F$  NMR (376 MHz,  $CDCl_3$ ):  $\delta$ (ppm) = -73.38, -71.49 (6F,  $PF_6$ ); ESI-MS ( $CH_3OH$ ):  $m/z$  587.05  $[M-Cl]^+$ .

**2-(6-(4-acetylphenyl)pyridin-2-yl)benzo[d]thiazole (7g3)**: Yield: 90%,  $R_f$  (16.5% ethyl acetate in hexane): 0.18;  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  (ppm) 2.66 (s, 3H,  $COCH_3$ ), 7.43 (t, 1H,  $J = 7.6$  Hz, ArCH), 7.51 (t, 1H,  $J = 7.6$  Hz, ArCH), 7.70 (d, 1H,  $J = 8$  Hz, ArCH), 7.87 (d, 1H,  $J = 8$  Hz, ArCH), 7.91-7.97 (m, 2H, ArCH), 8.04 (d, 1H,  $J = 8$  Hz, ArCH), 8.09 (d, 2H,  $J = 8$  Hz, ArCH), 8.24 (d, 1H,  $J = 8$  Hz, ArCH), 8.33 (d, 1H,  $J = 7.6$  Hz, ArCH);  $^{13}C$  NMR (100 MHz,  $CDCl_3$ ):  $\delta$  26.75 (Acetyl  $CH_3$ ), 119.71, 122.00, 122.06, 123.66, 125.74, 126.30, 127.05, 128.88, 136.35, 136.60, 137.58, 138.03, 142.35, 144.33, 151.39, 154.38, 155.63, 169.68, 197.74 (C=O); ESI-MS ( $CH_3OH$ ):  $m/z$  331.08  $[M+H]^+$ .

**$[(\eta^6-p\text{-cymene})RuCl\{2\text{-}(6\text{-}(4\text{-acetylphenyl)pyridin-2-yl)benzo[d]thiazole}\}PF_6$  (8g3)**: 41.25 mg (0.07 mmol, 93 %);  $Mr$  ( $C_{30}H_{28}N_2OPSClF_6Ru$ ) = 746.11 g/mol; Anal. calcd for  $C_{30}H_{28}N_2OPSClF_6Ru$  (%): C 48.29, H 3.78, N 3.75 Found: C 47.60, H 4.22, N 3.58. N 4.38.; Mp: 242-244°C decomp.;  $R_f$  (100% ethyl acetate): 0.24; IR ( $cm^{-1}$ ):  $\nu$  3302, 1670, 1600, 1419, 1267, 993, 839, 758;  $^1H$  NMR (400 MHz, DMSO- $d_6$ ):  $\delta$  (ppm) 1.18 (d, 6H,  $J = 7.2$  Hz, H-i, H-j), 2.4 (s, 3H,  $p\text{-cym} CH_3$ , H-a), 2.74 (s, 3H,  $COCH_3$ , H-20), 2.78-2.89 (m, 1H,  $p\text{-cym} CH$ , H-h), 3.93 (s, 3H, -OMe, H-19), 5.76 (d, 2H,  $J = 6.0$  Hz,  $p\text{-cym} ArH$ , H-e, H-f), 5.80 (d, 2H,  $J = 6.4$  Hz,  $p\text{-cym} ArH$ , H-c, H-d), 7.62 (d, 1H,  $J = 6.8$  Hz, H-2), 7.90 (d, 2H,  $J = 7.2$  Hz, ArH, H-3, H-9), 8.06 (t, 2H,  $J = 10.4$  Hz, ArH, H-4, H-10), 8.29 (t, 3H,  $J = 10.0$  Hz, ArH, H-1, H-11, H-14), 8.44-8.51 (m, 2H, ArH, H-13, H-17), 8.73 (d, 1H,  $J = 8.0$  Hz, ArH, H-18);  $^{13}C$  NMR (100 MHz, DMSO- $d_6$ ): (solubility problem);  $^{31}P$  NMR (400 MHz, DMSO):  $^{31}P$  NMR (162 MHz, DMSO- $d_6$ ):  $\delta$ (ppm) (-157.39)-(-131.04) (m, 1P,  $PF_6$ ).  $^{19}F$  NMR (376 MHz, DMSO- $d_6$ ):  $\delta$ (ppm) -71.03, -69.15 (6F,  $PF_6$ ); ESI-MS ( $CH_3OH$ ):  $m/z$  601.06  $[M-Cl]^+$ .

**5-chloro-2-(6-phenylpyridin-2-yl)benzo[d]thiazole (7I1)**: Yield: 92%,  $R_f$  (20% ethyl acetate in hexane): 0.55;  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  (ppm) 7.39 (d, 1H,  $J = 8$  Hz, ArCH), 7.48 (t, 1H,  $J = 7.2$  Hz, ArCH), 7.53 (t, 2H,  $J = 7.6$  Hz, ArCH), 7.86 (d, 2H,  $J = 8$  Hz, ArCH), 7.92 (t, 1H,  $J = 7.6$  Hz, ArCH), 8.08 (s, 1H, ArCH), 8.15 (d, 2H,  $J = 7.6$  Hz, ArCH), 8.26 (d, 1H,  $J = 7.6$  Hz, ArCH);  $^{13}C$  NMR (100 MHz,  $CDCl_3$ ):  $\delta$  118.99, 121.98, 122.72, 123.32, 126.07, 126.93, 128.90, 129.61, 132.18, 134.65, 137.96, 138.06, 150.68, 155.24, 157.09, 172.10; ESI-MS ( $CH_3OH$ ):  $m/z$  323.03  $[M+H]^+$ .

**$[(\eta^6-p\text{-cymene})RuCl\{5\text{-chloro-2-(6-phenylpyridin-2-yl)benzo[d]thiazole}\}PF_6$  (8I1)**: 54.5 mg (0.074 mmol, 95 %);  $Mr$  ( $C_{28}H_{25}N_2PSCl_2F_6Ru$ ) = 738.52 g/mol; Anal. calcd for  $C_{28}H_{25}N_2PSCl_2F_6Ru$  (%): C 45.54, H 3.41, N 3.79 Found: C 45.80, H 3.70, N 4.08.; Mp: 245-247°C decomp.;  $R_f$  (100% ethyl acetate): 0.23; IR ( $cm^{-1}$ ):  $\nu$  3306, 3078, 1672, 1600, 1429, 1269, 996, 829, 758;  $^1H$  NMR (400 MHz, DMSO- $d_6$ ):  $\delta$  (ppm) 0.65 (brs, 6H, H-i, H-j), 2.07 (s, 3H,  $p\text{-cym} CH_3$ , H-a), 3.16 (brs, 1H,  $p\text{-cym} CH$ , H-h), 5.69 (brs, 4H,  $p\text{-cym} ArH$ , H-c, H-d, H-e, H-f), 7.71-7.77 (m, 3H, H-15, H-16, H-17), 7.88 (dd, 1H,  $J_1 = 8.8$  Hz,  $J_2 = 1.6$  Hz, ArH, H-2), 8.01 (d, 1H,  $J = 7.6$  Hz, ArH, H-9), 8.09-8.12 (m, 3H, ArH, H-4, H-10, H-11), 8.41 (t, 1H,  $J = 7.6$  Hz, ArH, H-18), 8.48 (d, 1H,  $J = 8.8$  Hz, ArH, H-14), 8.68 (d, 1H,  $J = 7.6$  Hz, H-1);  $^{13}C$  NMR (100 MHz, DMSO- $d_6$ ): (solubility problem);  $^{31}P$  NMR (162 MHz, DMSO- $d_6$ ):  $\delta$ (ppm) (-157.43)-(-135.48) (m, 1P,  $PF_6$ );  $^{19}F$  NMR (376 MHz,  $CDCl_3$ ):  $\delta$ (ppm) -73.65, -71.75 (6F,  $PF_6$ ); ESI-MS ( $CH_3OH$ ):  $m/z$  593.02  $[M-Cl]^+$ .



**5-chloro-2-(6-(4-formylphenyl)pyridin-2-yl)benzo[d]thiazole (7I2):** Yield: 91%,  $R_f$  (20% ethyl acetate in hexane): 0.26; IR ( $\text{cm}^{-1}$ ):  $\nu$  3055, 2845, 1693, 1604, 1573, 1452, 1427, 1301, 1209, 1161, 1068, 987, 794;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 7.40 (d, 1H,  $J = 8$  Hz, ArCH), 7.87 (d, 1H,  $J = 8$  Hz, ArCH), 7.93-7.99 (m, 2H, ArCH), 8.03 (d, 2H,  $J = 8$  Hz, ArCH), 8.08 (s, 1H, ArCH), 8.32 (t, 3H,  $J = 8$  Hz, ArCH), 10.11 (s, 1H, CHO);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  119.57, 120.03, 122.55, 122.73, 123.43, 126.27, 127.47, 129.94, 130.24, 132.32, 134.50, 136.83, 138.23, 143.50, 151.09, 155.19, 155.50, 171.40, 191.89 (CHO); ESI-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  351.03  $[\text{M}+\text{H}]^+$ .

**$[(\eta^6\text{-}p\text{-cymene})\text{RuCl}\{5\text{-chloro-2-(6-(4-formylphenyl)pyridin-2-yl)benzo[d]thiazole}\}]\text{PF}_6$  (8I2):**

51.3 mg (0.067 mmol, 94 %);  $M_r$  ( $\text{C}_{29}\text{H}_{25}\text{N}_2\text{OPSCl}_2\text{F}_6\text{Ru}$ ) = 766.53 g/mol; Anal. calcd for  $\text{C}_{29}\text{H}_{25}\text{N}_2\text{OPSCl}_2\text{F}_6\text{Ru}$  (%): C 45.44, H 3.29, N 3.65 Found: C 45.72, H 3.57, N 3.80.; Mp: 242-244°C decomp.;  $R_f$  (100% ethyl acetate): 0.21; IR ( $\text{cm}^{-1}$ ):  $\nu$  3105, 2972, 1697, 1600, 1431, 1408, 1327, 1209, 1176, 1072, 929, 829, 742, 555;  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  (ppm) 0.69 (d, 6H,  $J = 16.4$  Hz, H-i, H-j), 2.08 (s, 3H,  $p\text{-cym}$   $\text{CH}_3$ , H-a), 2.79-2.84 (m, 1H,  $p\text{-cym}$  CH, H-h), 5.76-5.82 (m, 3H,  $p\text{-cym}$  ArH, H-d, H-e, H-f), 6.13 (brs, 1H,  $p\text{-cym}$  ArH, H-c), 7.93 (d, 1H,  $J = 5.6$  Hz, H-2), 8.10 (t, 1H,  $J = 8.0$  Hz, ArH, H-10), 8.15 (brs, 1H, ArH, H-9), 8.22-8.25 (m, 2H, ArH, H-1, H-11), 8.36 (d, 1H,  $J = 8.4$  Hz, ArH, H-17), 8.43-8.50 (m, 2H, ArH, H-14, H-15), 8.55 (d, 1H,  $J = 8.8$  Hz, H-4), 8.78 (d, 1H,  $J = 7.6$  Hz, H-18);  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO-}d_6$ ): (solubility problem);  $^{31}\text{P}$  NMR ( $\text{DMSO-}d_6$ , 162 MHz):  $\delta$ (ppm) (-153.01)-(-131.06) (m, 1P,  $\text{PF}_6$ );  $^{19}\text{F}$  NMR (376 MHz,  $\text{DMSO-}d_6$ ):  $\delta$ (ppm) -71.03, -69.14 (6F,  $\text{PF}_6$ ); ESI-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  621.01  $[\text{M-Cl}]^+$ .

**5-chloro-2-(6-(4-acetylphenyl)pyridin-2-yl)benzo[d]thiazole (7I3):** Yield: 96%,  $R_f$  (20% ethyl acetate in hexane): 0.21;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 2.67 (s, 3H,  $\text{COCH}_3$ ) 7.39 (d, 1H,  $J = 8$  Hz, ArCH), 7.70 (d, 1H,  $J = 8$  Hz, ArCH), 7.85-7.94 (m, 3H, ArCH), 8.03-8.10 (m, 3H, ArCH), 8.22 (d, 1H,  $J = 7.6$  Hz, ArCH), 8.30 (d, 1H,  $J = 7.6$  Hz, ArCH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  26.82 (Acetyl  $\text{CH}_3$ ), 119.83, 122.42, 122.74, 123.39, 126.23, 127.06, 127.46, 128.93, 129.03, 132.30, 134.59, 137.60, 138.18, 142.21, 150.98, 155.18, 155.71, 171.57, 197.83 (C=O); ESI-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  365.04  $[\text{M}+\text{H}]^+$ .

**$[(\eta^6\text{-}p\text{-cymene})\text{RuCl}\{5\text{-chloro-2-(6-(4-acetylphenyl)pyridin-2-yl)benzo[d]thiazole}\}]\text{PF}_6$  (8I3):**

49.7 mg (0.064 mmol, 93 %);  $M_r$  ( $\text{C}_{30}\text{H}_{27}\text{N}_2\text{OPSCl}_2\text{F}_6\text{Ru}$ ) = 780.55 g/mol; Anal. calcd for  $\text{C}_{30}\text{H}_{27}\text{N}_2\text{OPSCl}_2\text{F}_6\text{Ru}$  (%): C 46.16, H 3.49, N 3.59 Found: C 46.41, H 3.77, N 3.85.; Mp: 235-237°C decomp.;  $R_f$  (100% ethyl acetate): 0.22; IR ( $\text{cm}^{-1}$ ):  $\nu$  2972, 1687, 1600, 1402, 1263, 1226, 1182, 1072, 927, 833, 744, 555;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 0.61 (d, 3H,  $J = 6.8$  Hz, H-j), 0.87 (d, 3H,  $J = 6.8$  Hz, H-i), 2.11 (s, 3H,  $p\text{-cym}$   $\text{CH}_3$ , H-a), 2.33-2.38 (m, 1H,  $p\text{-cym}$  CH, H-h), 2.69 (3H,  $-\text{COCH}_3$ , H-20), 5.40-5.46 (m, 2H,  $p\text{-cym}$  ArH, H-e, H-f), 5.58 (d, 2H,  $J = 6.0$  Hz,  $p\text{-cym}$  ArH, H-c, H-d), 7.66 (d, 2H,  $J = 7.2$  Hz, H-2, H-9), 7.78-7.81 (m, 1H, ArH, H-10), 7.96 (brs, 1H, ArH, H-1), 8.01 (t, 2H,  $J = 8.4$  Hz, ArH, H-11, H-17), 8.22-8.24 (m, 4H, ArH, H-4, H-14, H-15, H-18);  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO-}d_6$ ): (solubility problem);  $^{31}\text{P}$  NMR ( $\text{DMSO-}d_6$ , 162 MHz):  $\delta$ (ppm) (-157.40)-(-135.45) (m, 1P,  $\text{PF}_6$ );  $^{19}\text{F}$  NMR ( $\text{DMSO-}d_6$ , 376 MHz):  $\delta$ (ppm) -71.03, -69.15 (6F,  $\text{PF}_6$ ); ESI-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  635.03  $[\text{M-Cl}]^+$ .

**5-chloro-2-(6-(4-chlorophenyl)pyridin-2-yl)benzo[d]thiazole (7I4):** Yield: 95%;  $R_f$  (20% ethyl acetate in hexane): 0.47;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 7.39 (d, 1H,  $J = 8$  Hz,

ArCH), 7.49 (d, 2H,  $J = 8.8$  Hz, ArCH), 7.80-7.87 (q, 2H, ArCH), 7.91 (t, 1H,  $J = 8$  Hz, ArCH), 8.05 (m, 3H, ArCH), 8.26 (d, 1H,  $J = 8$  Hz, ArCH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  119.24, 121.67, 122.69, 123.37, 126.15, 128.17, 129.06, 132.25, 134.60, 135.78, 136.48, 138.07, 150.80, 155.22, 155.87, 171.72; ESI-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  356.99  $[\text{M}+\text{H}]^+$ .

**$[(\eta^6\text{-}p\text{-cymene})\text{RuCl}\{5\text{-chloro-2-(6-(4-chlorophenyl)pyridin-2-yl)benzo[d]thiazole}\}]\text{PF}_6$  (814):** 55.85 mg (0.072 mmol, 93 %);  $M_r$  ( $\text{C}_{28}\text{H}_{24}\text{N}_2\text{PSCl}_3\text{F}_6\text{Ru}$ ) = 772.96 g/mol; Anal. calcd for  $\text{C}_{28}\text{H}_{24}\text{N}_2\text{PSCl}_3\text{F}_6\text{Ru}$  (%): C 43.51, H 3.13, N 3.62 Found: C 43.81, H 3.40, N 3.86.; Mp: 237-239°C decomp.;  $R_f$  (100% ethyl acetate): 0.25; IR ( $\text{cm}^{-1}$ ):  $\nu$  2974, 1737, 1597, 1487, 1406, 1325, 1276, 1182, 1093, 833, 808, 555;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$ (ppm) 1.27 (d, 6H,  $J = 6.8$  Hz,  $p$ -cym  $\text{CH}_3$ , H-i, H-j), 2.14 (s, 3H,  $p$ -cym  $\text{CH}_3$ , H-a), 2.89 (sept, 1H,  $J = 6.8$  Hz,  $p$ -cym CH, H-h), 5.34 (d, 2H,  $J = 5.6$  Hz,  $p$ -cym ArH, H-e H-f), 5.46 (d, 2H,  $J = 5.6$  Hz,  $p$ -cym ArH, H-c, H-d), 7.49 (d,  $J = 8.4$  Hz, 1H, ArH, H-15), 7.65 (brs, 3H, ArH, H-2, H-9, H-17), 7.82-7.88 (m, 2H, ArH, H-1, H-10), 7.98 (s, 1H, ArH, H-11), 8.08 (d, 1H,  $J = 8.0$  Hz, ArH, H-4), 8.28 (d, 2H,  $J = 7.2$  Hz, ArH, H-14, H-18);  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO-}d^6$ ): (solubility problem);  $^{31}\text{P}$  NMR (162 MHz,  $\text{DMSO-}d^6$ ):  $\delta$ (ppm) (-157.40)-(-135.45) (m, 1P,  $\text{PF}_6$ );  $^{19}\text{F}$  NMR (376 MHz,  $\text{DMSO-}d^6$ ):  $\delta$ (ppm) = -71.05, -69.15 (6F,  $\text{PF}_6$ ); ESI-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  626.98  $[\text{M-Cl}]^+$ .

**5-chloro-2-(6-(4-fluorophenyl)pyridin-2-yl)benzo[d]thiazole (715):** Yield: 95%,  $R_f$  (20% ethyl acetate in hexane): 0.15;  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 7.21 (t, 2H,  $J = 8.8$  Hz, ArH), 7.39 (d, 1H,  $J = 8.4$  Hz, ArH), 7.81 (d, 1H,  $J = 7.6$  Hz, ArH), 7.85-7.93 (m, 2H, ArH), 8.08 (s, 1H, ArH), 8.12-8.15 (m, 2H, ArH), 8.26 (d, 1H,  $J = 7.6$  Hz, ArH);  $^{13}\text{C}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  115.7, 115.9, 118.9, 121.6, 122.7, 123.4, 126.1, 128.7, 128.8, 132.2, 134.2, 134.2, 134.6, 138.0, 150.7, 155.2, 156.1, 171.8;  $^{19}\text{F}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$ (ppm) = -112.00 (s, 1F); LC-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  341.02  $[\text{M}+\text{H}]^+$ .

**$[(\eta^6\text{-}p\text{-cymene})\text{RuCl}\{5\text{-chloro-2-(6-(4-fluorophenyl)pyridin-2-yl)benzo[d]thiazole}\}]\text{PF}_6$  (815):**

50.5 mg (0.067 mmol, 92 %);  $M_r$  ( $\text{C}_{28}\text{H}_{24}\text{N}_2\text{PSCl}_2\text{F}_7\text{Ru}$ ) = 756.51 g/mol; Anal. calcd for  $\text{C}_{28}\text{H}_{24}\text{N}_2\text{PSCl}_2\text{F}_7\text{Ru}$  (%): C 44.46, H 3.20, N 3.70 Found: C 44.71, H 3.48, N 4.06.; Mp: 236-238°C decomp.;  $R_f$  (100% ethyl acetate): 0.24; IR ( $\text{cm}^{-1}$ ):  $\nu$  2976, 1736, 1599, 1477, 1406, 1327, 1274, 1181, 1094, 836, 808, 555;  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}$ ):  $\delta$  (ppm) solubility problem;  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO-}d^6$ ): (solubility problem);  $^{31}\text{P}$  NMR (162 MHz,  $\text{DMSO-}d^6$ ):  $\delta$ (ppm) (-157.38)-(-135.43) (m, 1P,  $\text{PF}_6$ );  $^{19}\text{F}$  NMR (376 MHz,  $\text{DMSO-}d^6$ ):  $\delta$ (ppm) -79.76, -77.23 (1F), -71.04, -69.15 (6F,  $\text{PF}_6$ ); LC-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  611.01  $[\text{M-Cl}]^+$ .

**5-chloro-2-(6-(4-(trifluoromethyl)phenyl)pyridin-2-yl)benzo[d]thiazole (716):** Yield: 92%,  $R_f$  (16.5% ethyl acetate in hexane): 0.42;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 7.39 (d, 1H,  $J = 8.4$  Hz, ArH), 7.64 (t, 1H,  $J = 8$  Hz, ArH), 7.72 (d, 1H,  $J = 7.6$  Hz, ArH), 7.85-7.88 (m, 2H, ArH), 7.95 (t, 1H,  $J = 8$  Hz, ArH), 8.07 (s, 1H, ArH), 8.31 (brs, 2H, ArH), 8.39 (s, 1H, ArH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  119.7, 121.9, 122.7, 123.4, 123.7, 123.8, 126.2, 129.4, 130.1, 131.2, 131.5, 132.3, 134.6, 138.2, 138.8, 150.8, 155.2, 155.4, 171.5;  $^{19}\text{F}$  NMR (376 MHz,  $\text{CDCl}_3$ ):  $\delta$ (ppm) -62.63 (s, 3F); LC-MS ( $\text{CH}_3\text{OH}$ ):  $m/z$  391.02  $[\text{M}+\text{H}]^+$

**$[(\eta^6\text{-}p\text{-cymene})\text{RuCl}\{5\text{-chloro-2-(6-(4-(trifluoromethyl)phenyl)pyridin-2-yl)benzo[d]thiazole}\}]\text{PF}_6$  (816):**

48.5 mg (0.06 mmol, 94 %);  $M_r$  ( $\text{C}_{29}\text{H}_{24}\text{N}_2\text{PSCl}_2\text{F}_9\text{Ru}$ ) = 806.51 g/mol; Anal. calcd for  $\text{C}_{29}\text{H}_{24}\text{N}_2\text{PSCl}_2\text{F}_9\text{Ru}$  (%): C 43.19, H 3.00, N 3.47 Found: C 43.51, H 3.34, N 3.27.;  $R_f$  (100%

ethyl acetate): 0.20; Mp: 239-241°C decomp.; IR (cm<sup>-1</sup>):  $\nu$  3120, 3041, 2972, 1598, 1552, 1406, 1313, 1226, 1124, 1072, 929, 831, 758, 555; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  (ppm) 1.18 (d, 6H, *J* = 6.8 Hz, H-i, H-j), 2.08 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.79-2.86 (m, 1H, *p*-cym CH, H-h), 5.77 (d, 2H, *J* = 6.4 Hz, *p*-cym ArH, H-e, H-f), 5.81 (d, 2H, *J* = 6.4 Hz, *p*-cym ArH, H-c, H-d), 7.56-7.59 (m, 1H, H-10), 7.87 (d, 1H, *J* = 8.0 Hz, ArH, H-2), 7.92 (d, 1H, *J* = 8.8 Hz, ArH, H-9), 7.99 (t, 1H, *J* = 8.0 Hz, ArH, H-17), 8.15 (brs, 1H, ArH, H-15), 8.21 (brs, 1H, H-1), 8.32 (d, 1H, *J* = 7.6 Hz, H-11), 8.47 (d, 1H, *J* = 8.0 Hz, H-14), 8.56 (d, 1H, *J* = 8.4 Hz, H-18), 8.79 (d, 1H, *J* = 8.0 Hz, H-4); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>): (solubility problem); <sup>31</sup>P NMR (162 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ (ppm) (-157.39)-(-131.04) (m, 1P, PF<sub>6</sub>); <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ (ppm) = -71.04, -69.15 (6F, PF<sub>6</sub>), -60.68 (s, 3F, CF<sub>3</sub>); ESI-MS (CH<sub>3</sub>OH): *m/z* 661.01 [M-Cl]<sup>+</sup>.

**.5-chloro-2-(6-(naphthalen-1-yl)pyridin-2-yl)benzo[d]thiazole (717):** Yield: 95%, R<sub>f</sub> (20% ethyl acetate in hexane): 0.65; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) 7.39 (t, 1H, *J* = 8 Hz, ArC), 7.52-7.55 (m, 2H, ArC), 7.58-7.62 (m, 1H, ArC), 7.69-7.73 (m, 2H, ArC), 7.81-7.87 (m, 1H, ArC), 7.95-8.01 (m, 3H, ArC), 8.08 (d, 1H, *J* = 12.0 Hz, ArC), 8.28-8.33 (m, 1H, ArC), 8.38 (d, 1H, *J* = 8 Hz, ArC); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  118.9, 119.6, 122.7, 122.8, 123.3, 123.5, 125.3, 125.6, 126.0, 126.5, 126.6, 126.9, 127.9, 128.5, 129.5, 129.9, 131.1, 132.2, 134.1, 137.3, 137.6, 139.3; LC-MS (CH<sub>3</sub>OH): *m/z* 373.05 [M+H]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)RuCl{5-chloro-2-(6-(naphthalen-1-yl)pyridin-2-yl)benzo[d]thiazole}]PF<sub>6</sub> (817):**

50.7 mg (0.064 mmol, 96 %); *Mr* (C<sub>32</sub>H<sub>27</sub>N<sub>2</sub>PSCl<sub>2</sub>F<sub>6</sub>Ru) = 788.57 g/mol; Anal. calcd for C<sub>32</sub>H<sub>27</sub>N<sub>2</sub>PSCl<sub>2</sub>F<sub>6</sub>Ru (%): C 48.74, H 3.45, N 3.55 Found: C 48.97, H 3.77, N 3.16.; Mp: 240-242°C decomp. ; R<sub>f</sub> (100% ethyl acetate): 0.27; IR (cm<sup>-1</sup>):  $\nu$  3122, 3045, 2806, 1734, 1593, 1404, 1182, 1072, 925, 829, 781, 553; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  (ppm) 1.18 (d, 6H, *J* = 7.6 Hz, H-i, H-j), 2.07 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.78-2.85 (m, 1H, *p*-cym CH, H-h), 5.75 (d, 2H, *J* = 6.4 Hz, *p*-cym ArH, H-e, H-f), 5.80 (d, 2H, *J* = 6.0 Hz, *p*-cym ArH, H-c, H-d), 7.84-7.90 (m, 2H, H-1, H-2), 7.92 (d, 1H, *J* = 5.6 Hz, ArH, H-15), 7.99 (t, 1H, *J* = 8.0 Hz, ArH, H-9), 8.06 (d, 2H, *J* = 6.8 Hz, ArH, H-1, H-10), 8.19-8.21 (m, 1H, ArH, H-11), 8.26 (d, 1H, *J* = 8.0 Hz, H-19), 8.32 (d, 1H, *J* = 7.6 Hz, H-17), 8.36 (d, 1H, *J* = 8.0 Hz, H-4), 8.47 (t, 1H, *J* = 7.6 Hz, H-18), 8.55 (d, 1H, *J* = 8.8 Hz, H-20), 8.82 (1H, d, *J* = 7.6 Hz, H-14).; <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>): (solubility problem); <sup>31</sup>P NMR (162 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ (ppm) (-157.40)-(-131.06) (m, 1P, PF<sub>6</sub>); <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>):  $\delta$ (ppm) -71.03, -69.14 (6F, PF<sub>6</sub>); LC-MS (CH<sub>3</sub>OH): *m/z* 643.03 [M-Cl]<sup>+</sup>.

**2-(6-(benzo[b]thiophen-2-yl)pyridin-2-yl)-5-chlorobenzo[d]thiazole (718):** Yield: 90%; R<sub>f</sub> (16.5% ethyl acetate in hexane): 0.53; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm) = 7.39-7.42 (m, 3H, ArH), 7.50 (s, 1H, ArH), 7.57 (d, 1H, *J* = 7.6 Hz, ArH), 7.70 (d, 1H, *J* = 8 Hz, ArCH), 7.85 (s, 1H, ArCH), 7.87-7.90 (m, 2H, ArCH), 8.06 (s, 1H, ArCH), 8.29 (d, 1H, *J* = 7.6 Hz, ArCH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  119.6, 121.4, 122.2, 122.8, 123.7, 124.8, 124.9, 126.5, 128.5, 128.6, 129.9, 132.1, 132.2, 132.5, 134.6, 139.3, 141.8, 151.9, 154.9; LC-MS (CH<sub>3</sub>OH): *m/z* 379.01 [M+H]<sup>+</sup>.

**[( $\eta^6$ -*p*-cymene)Ru-2-(6-(benzo[b]thiophen-2-yl)pyridin-2-yl)-5-chlorobenzo[d]thiazole (818):**

49.8 mg (0.063 mmol, 95 %); *Mr* (C<sub>30</sub>H<sub>25</sub>N<sub>2</sub>PS<sub>2</sub>Cl<sub>2</sub>F<sub>6</sub>Ru) = 794.60 g/mol; Anal. calcd for C<sub>30</sub>H<sub>25</sub>N<sub>2</sub>PS<sub>2</sub>Cl<sub>2</sub>F<sub>6</sub>Ru (%): C 45.35, H 3.17, N 3.53 Found: C 45.72, H 3.48, N 3.26.; Mp: 242-244°C decomp. ; R<sub>f</sub> (100% ethyl acetate): 0.29; IR (cm<sup>-1</sup>):  $\nu$  3126, 3045, 2973, 1589, 1552,

1409, 1323, 1226, 1126, 1071, 929, 834, 768, 554; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ (ppm) 1.18 (d, 6H, *J* = 7.2 Hz, H-i, H-j), 2.08 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.79-2.86 (m, 1H, *p*-cym CH, H-h), 5.77 (d, 2H, *J* = 6.4 Hz, *p*-cym ArH, H-e, H-f), 5.81 (d, 2H, *J* = 6.0 Hz, *p*-cym ArH, H-c, H-d), 7.57-7.59 (m, 4H, H-2, H-15, H-16, H-17), 7.87 (d, 1H, *J* = 7.6 Hz, ArH, H-1), 7.92 (t, 1H, *J* = 9.2 Hz, ArH, H-14), 8.0 (t, 1H, *J* = 8.0 Hz, ArH, H-18), 8.21-8.23 (m, 2H, ArH, H-9, H-11), 8.25 (s, 1H, H-4), 8.33 (d, 1H, *J* = 7.6 Hz, H-10); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>): δ 18.3 (Me, C-a, *p*-cymene), 21.9 (Me, C-j, *p*-cymene), 24.4 (Me, C-i, *p*-cymene), 30.5 (CH, C-h, *p*-cymene), 84.8 (ArCH, C-f, *p*-cymene), 85.9 (ArCH, C-e, *p*-cymene), 86.8 (ArCH, C-d, *p*-cymene), 87.6 (ArCH, C-c, *p*-cymene), 100.6 (ArC, C-g, *p*-cymene), 106.9 (ArC, C-b, *p*-cymene), 120.4 (ArCH, C-4), 121.0 (ArCH, C-14), 122.4 (ArCH, C-18), 123.2 (ArCH, C-9), 124.7 (ArCH, C-15), 126.6 (ArCH, C-1), 126.9 (ArCH, C-11), 129.2 (ArCH, C-16), 129.2 (ArCH, C-17), 129.3 (ArCH, C-2), 131.1 (ArC, C-3), 131.8 (ArCH, C-5), 131.9 (ArC, C-20), 132.1 (ArC, C-19), 134.6 (ArCH, C-10), 141.6 (ArC, C-13), 144.8 (ArC, C-8), 151.1 (ArC, C-6), 154.9 (ArC, C-7), 169.6 (ArC, C-12); <sup>31</sup>P NMR (162 MHz, DMSO-*d*<sub>6</sub>): δ(ppm) = (-157.38)-(-131.03) (m, 1P, PF<sub>6</sub>); <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>): δ(ppm) = -71.06, -69.17 (6F, PF<sub>6</sub>); ESI-MS (CH<sub>3</sub>OH): *m/z* 648.99 [M-Cl]<sup>+</sup>.

**2-(6-(benzofuran-2-yl)pyridin-2-yl)-5-chlorobenzo[d]thiazole (7I9):** Yield: 94%, *R<sub>f</sub>* (16.5% ethyl acetate in hexane): 0.62; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ (ppm) 7.15 (s, 1H, ArCH), 7.52-7.55 (m, 1H, ArCH), 7.40 (d, 1H, *J* = 8 Hz, ArCH), 7.53-7.58 (m, 2H, ArCH), 7.62 (d, 1H, *J* = 6.8 Hz, ArCH), 7.70 (t, 1H, *J* = 7.6 Hz, ArCH), 7.86 (d, 1H, *J* = 8.4 Hz, ArCH), 7.92-8.01 (m, 1H, ArCH), 8.05 (s, 1H, ArCH), 7.29 (d, *J* = 8.0 Hz, 1H, ArCH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 103.70, 105.81, 111.29, 119.59, 121.40, 121.89, 122.81, 123.36, 123.47, 125.09, 126.48, 129.96, 132.48, 134.60, 137.97, 139.29, 141.78, 151.98, 154.96, 155.09; LC-MS (CH<sub>3</sub>OH): *m/z* 363.03 [M+H]<sup>+</sup>.

### **[(η<sup>6</sup>-*p*-cymene)Ru-2-(6-(benzofuran-2-yl)pyridin-2-yl)-5-chlorobenzo[d]thiazole (8I9):**

50.9 mg (0.065 mmol, 95 %); *Mr* (C<sub>30</sub>H<sub>25</sub>N<sub>2</sub>OPSCl<sub>2</sub>F<sub>6</sub>Ru) = 778.54 g/mol; Anal. calcd for C<sub>30</sub>H<sub>25</sub>N<sub>2</sub>OPSCl<sub>2</sub>F<sub>6</sub>Ru (%): C 46.28, H 3.24, N 3.60 Found: C 46.62, H 3.71, N 3.92.; Mp: 244-246°C decomp.; *R<sub>f</sub>* (100% ethyl acetate): 0.28; IR (cm<sup>-1</sup>): ν 3126, 3040, 2970, 1589, 1552, 1408, 1328, 1226, 1125, 1071, 929, 834, 758, 555; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ (ppm) 1.18 (d, 6H, *J* = 7.2 Hz, H-i, H-j), 2.08 (s, 3H, *p*-cym CH<sub>3</sub>, H-a), 2.79-2.86 (m, 1H, *p*-cym CH, H-h), 5.77 (d, 2H, *J* = 6.4 Hz, *p*-cym ArH, H-e, H-f), 5.81 (d, 2H, *J* = 6.0 Hz, *p*-cym ArH, H-c, H-d), 7.57-7.59 (m, 2H, H-16, H-17), 7.73 (d, 1H, *J* = 8.4 Hz, H-14), 7.87 (d, 1H, *J* = 8.0 Hz, ArH, H-2), 8.01 (t, 2H, *J* = 8.0 Hz, ArH, H-15, H-18), 8.21-8.23 (m, 2H, ArH, H-1, H-10), 8.25 (s, 1H, H-4), 8.33 (d, 2H, *J* = 7.2 Hz, H-9, H-11); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>): Solubility problem; <sup>31</sup>P NMR (100 MHz, DMSO-*d*<sub>6</sub>): δ(ppm) (-157.38)-(-135.43) (m, 1P, PF<sub>6</sub>); <sup>19</sup>F NMR (100 MHz, DMSO-*d*<sub>6</sub>): δ(ppm) = -71.06, -69.17 (6F, PF<sub>6</sub>); LC-MS (CH<sub>3</sub>OH): *m/z* 633.01 [M-Cl]<sup>+</sup>.

### ***In vitro* cytotoxic activities (MTT assay)<sup>1</sup>**

MTT assay, a standard protocol, has been used to determine the *in vitro* cytotoxicity.<sup>2</sup> This assay is based on the reduction of the yellow MTT tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide) by mitochondrial dehydrogenases to form a blue MTT formazan in viable cells. Synthesized ruthenium(II)-*p*-cymene-2-aryl benzimidazole (BIZ), benzothiazole (BTZ) and benzoxazole (BOZ) scaffolds were accomplished above-mentioned to the experiment by dissolving in 0.1% DMSO followed by serial dilution with medium. Two different types of cancer cell lines i.e. human epitheloid cervix carcinoma (HeLa), human colorectal adenocarcinoma cell line (Caco-2), and one normal human embryonic kidney cells (HEK-293) were used in the assay. Nearly 1 × 10<sup>4</sup> cells per well for all the three cell lines were

cultured in 100  $\mu\text{L}$  of a growth medium in 96-well plates and incubated at 37  $^{\circ}\text{C}$  under a 5%  $\text{CO}_2$  atmosphere. After that the cells were treated with different concentrations of the complexes (1-200  $\mu\text{M}$ ) in the volume of 100  $\mu\text{M}$ /well. cisplatin, chlorpromazine and RAPTA-C have been used as standard positive control drug. It was also mentioned that cells are in the control wells filled with the same volume of medium containing 0.1% DMSO. After 24 h (for HeLa and HEK-293) and 48 h (for Caco-2), the medium was superfluous and cell cultures were subjected to incubate with 100  $\mu\text{L}$  MTT reagent (1 mg/ml) for 5 h at 37 $^{\circ}$  C. Then the suspension was placed on microvibrator for 10-15 min and sequentially the absorbance was recorded by the ELISA reader at  $\lambda = 570$  nm. The experiment was also performed in triplicate. The data were expressed as the growth inhibition percentage calculated according to the equation: % cell viability =  $[\text{OD}_{\text{sample}} - \text{OD}_{\text{blank}} / \text{OD}_{\text{control}} - \text{OD}_{\text{blank}}] \times 100$ , where  $\text{OD}_{\text{sample}}$  is the measured absorbance in wells containing samples,  $\text{OD}_{\text{control}}$  is the absorbance measured for cells with a medium and a vehicle and  $\text{OD}_{\text{blank}}$  is the absorbance measured for blank well (no cells). Dose response curve was fitted in Origin 8.5 software and  $\text{IC}_{50}$  was calculated.

### Conductivity measurement<sup>1</sup>

To confirm the interaction of the complexes with water, DMSO, GSH and CT-DNA solutions, conductivity of the prepared complexes were performed using conductivity-TDS meter-307 (Systronics, India) and cell constant 1.0  $\text{cm}^{-1}$ .<sup>3</sup> Rate of conductivity was also measured in different PH medium. Time dependent Conductivity measurement was also performed.

### Cellular imaging assay<sup>1</sup>

Cellular imaging study was performed by using cancerous HeLa cell line procured from NCCS. 6 well plates have been used for this study. Cultured cells with 80% confluence were taken followed by trypsinisation using 1-2 ml of 1X trypsin. Then, it was transferred to fresh 15 ml falcon tube and centrifuged for 2000 rpm for 1-5 min. DMEM fresh media (80 $\mu\text{l}$ ) was added to the pellet formed at the bottom of the tube and the cells were seeded in 6 well plates. Subsequently, the complex **11j'** in PBS buffer was added to the well plates. After incubated for 2-4 h at 37  $^{\circ}\text{C}$ , all the wells were washed twice with PBS buffer (pH 7.4). Finally, the fluorescence images were recorded using the glass slides with an Olympus Fluorescence microscope at 480-550 nm excitations.<sup>4</sup>

### DNA binding study<sup>1</sup>

The calf-thymus DNA (CT-DNA) binding tendency of the complexes was monitored by electronic spectra and competitive binding assay using a classical DNA intercalator, ethidium bromide (EtBr) by fluorescence spectroscopy.

### UV-visible studies<sup>1</sup>

DNA binding experiments was conducted by using complex **5I** and **11c** in Tris-HCl buffer (5 mM Tris-HCl in water, pH 7.4) in water medium.<sup>5</sup> The concentration of ct-DNA was determined from its absorbance intensity at 260 nm and its known molar absorption coefficient value 6600  $\text{M}^{-1} \text{cm}^{-1}$ . Same concentration of DNA was taken both in the sample and reference in cuvettes. UV titration was conducted by subsequent increase of ct-DNA concentration. The sample was equilibrated with ct-DNA for about 5 min before each measurement. After that absorbance of the complex were estimated after each 5  $\mu\text{L}$  addition of ct-DNA. The intrinsic DNA binding constant ( $K_b$ ) was calculated using the equation (i):

$$\frac{[DNA]}{(\varepsilon_a - \varepsilon_f)} = \frac{[DNA]}{(\varepsilon_b - \varepsilon_f)} + \frac{1}{K_b(\varepsilon_a - \varepsilon_f)} \quad (i)$$

Where [DNA] is the concentration of DNA in the base pairs,  $\varepsilon_a$  is the apparent extinction coefficient observed for the complex,  $\varepsilon_f$  corresponds to the extinction coefficient of the complex in its free form, and  $\varepsilon_b$  refers to the extinction coefficient of the complex when fully bound to DNA. Data were plotted using Origin 8.5 software to obtain the  $[DNA]/(\varepsilon_a - \varepsilon_f)$  vs. [DNA] linear plot. The ratio of the slope to intercept from the linear fit gives the value of the intrinsic binding constant ( $K_b$ ).

### Fluorescence study<sup>1</sup>

The emission property of all the synthesized complexes was investigated by using spectrofluorometric method. Fluorescence quantum yield ( $\Phi$ ) of all the prepared complexes performed in water solution were calculated by employing the comparative William's method which involves the use of well-characterized standard with the known quantum yield value.<sup>6</sup> Quinine sulfate was used as reference fluorophore excited at 350 nm and emission at 452 nm, quantum yield ( $\Phi_R$ ) = 0.50 in 1N H<sub>2</sub>SO<sub>4</sub>. The gradients of the plots are proportional to the quantum yield ( $\Phi$ ) of the studied system. The data obtained and quantum yield value calculated according to the equation (ii):

$$\Phi = \Phi_R \times (I_S/I_R) \times (OD_R/OD_S) \times (\eta_S/\eta_R) \quad (ii)$$

Where,  $\Phi$  = Quantum yield, I = Peak Area, OD = absorbance at  $\lambda_{max}$ ,  $\eta$  = Refractive index of solvent and reference. Quinine Sulphate was used as a standard for calculating emission of quantum yield. 0.5 M H<sub>2</sub>SO<sub>4</sub> was used as solvent for the standard and water for synthesized complexes.

### Ethidium bromide displacement assay<sup>1</sup>

The ethidium bromide fluorescence displacement assay was performed to identify the mode of binding between the potent complexes with DNA.<sup>7</sup> The intercalation of EthB to DNA is accompanied by strong fluorescence emission owing to the formation of the EtBr-DNA complex. Once a second molecule intercalates into DNA, there is a decrease of number of binding sites on the DNA available to EtBr giving rise to reduction in the fluorescence intensity. The apparent binding constant ( $K_{app}$ ) of the complex to CT-DNA was determined from the emission spectral measurements using ethidium bromide (EtBr) as a spectral probe in 5 mM Tris-HCl buffer (pH 7.4). EtBr showed no apparent emission in Tris-buffer medium because of fluorescence quenching of free EthB by solvent molecules.<sup>8</sup> The emission intensity gets significantly enhanced due to its intercalative binding to duplex DNA. A competitive binding of the complex to DNA is found to reduce the EthB emission intensity. The relative binding propensity of the complex to DNA was estimated from the reduction of the emission intensity. The values of the apparent binding constant ( $K_{app}$ ) were obtained by using the (iii) equation:

$$K_{app} \times [Complex]_{50} = K_{EtBr} \times [EtBr] \quad (iii)$$

where  $K_{app}$  is the apparent binding constant of the complex studied,  $[Complex]_{50}$  is the concentration of the complex at 50% quenching of DNA-bound ethidium bromide emission

intensity,  $K_{\text{EthB}}$  is the binding constant of the EtBr ( $K_{\text{EtBr}} = 1.0 \times 10^7 \text{ M}^{-1}$ ), and  $[\text{EtBr}]$  is the concentration of ethidium bromide ( $8 \mu\text{M}$ ). The Stern-Volmer quenching constant ( $K_{\text{SV}}$ ) has been calculated by using Stern-Volmer equation. Stern-Volmer plots of  $F_0/F$  vs.  $[\text{Complex}]$  was prepared using the corrected fluorescence data taking into account the effect of dilution. Linear fit of the data using the equation (iv):<sup>9</sup>

$$I_0/I = 1 + K_{\text{SV}} [Q] \quad (\text{iv})$$

Where  $F_0$  and  $F$  are the emission intensities of EthB-DNA in the absence and in the presence of complex of concentration  $[Q]$ , gave the quenching constant ( $K_{\text{SV}}$ ) using Origin Pro 8.5 software.

### Protein binding studies<sup>1</sup>

Serum albumin proteins constitute a major component in blood plasma proteins and plays important roles in drug transport and metabolism.<sup>10</sup> The interaction of the drug with bovine serum albumin (BSA), a structural homolog with human serum albumin (HSA) has been studied from tryptophan emission quenching experiment. Emission intensity of BSA at  $\lambda = 340 \text{ nm}$  decreases gradually with increasing the complex concentration, which confirms that the interaction between the complex and BSA have occurred. The complex solutions were gradually added to the solution of BSA ( $2 \mu\text{M}$ ) in  $5 \text{ mM}$  Tris-HCl/NaCl buffer ( $\text{pH } 7.2$ ) and the quenching of the emission signals at  $340 \text{ nm}$  ( $\lambda_{\text{ex}} = 295 \text{ nm}$ ) were recorded. The quenching constant ( $K_{\text{BSA}}$ ) has been determined quantitatively by using Stern-Volmer equation. Stern-Volmer plots of  $F_0/F$  vs.  $[\text{Complex}]$  was made using the corrected fluorescence data taking into account the effect of dilution. Linear fit of the data using the equation (v):

$$I_0/I = 1 + K_{\text{BSA}} [Q] = 1 + k_q \tau_0 [Q] \quad (\text{v})$$

Where,  $F_0$  and  $F$  are the emission intensities of BSA in the absence and in the presence of quencher of concentration  $[Q]$ , gave the quenching constant ( $K_{\text{BSA}}$ ) using Origin Pro 8.0 software.  $k_q$  is the quenching rate constant,  $\tau_0$  is the average lifetime of the tryptophan in BSA without quencher reported as  $1 \times 10^{-8} \text{ s}$ . For such static quenching interaction, the binding constant ( $K$ ) and the number of binding sites ( $n$ ) can be determined according to the Scatchard equation (vi).<sup>11</sup>

$$\log(I_0 - I/I) = \log K + n \log [Q] \quad (\text{vi})$$

### Density functional theory

All theoretical calculations were done by using the computational code Gaussian 09W.<sup>12</sup> To avoid computational time and complexity, the 3D structure was calculated by applying the semi-empirical PM6 method in the gas phase. The resulting geometry were verified as minima by frequency calculation and the energy of the calculated structure was estimated by applying the time depended density functional theory (TD-DFT) method by using Becke 3-Parameter, Lee, Yang and Parr (B3LYP) functional and the 6-311G(d,p) basis set. The NBO program is embedded in Gaussian 09 package used for calculations was developed at optimized molecules by applying Hartree-Fock (HF) method using 6-311G(d,p) basis set.



## MTT assay of compound 11j in HT-29

HT-29 and HeLa cells were grown in 96-well plates at 5000 cells per well. Cells were allowed to grow for 24 hours and followed by treated with the drug **11j** at different concentrations (1  $\mu\text{M}$  to 15  $\mu\text{M}$ ). Twenty-four hours later, 10 $\mu\text{L}$  of 3-(4,4-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/mL in PBS) was added to each well, and the plate was incubated at 37 °C for 4 hrs. Absorbance was measured on MULTISCAN sky plate reader (Thermo scientific) at a wavelength of 570 nm. The data was analysed and EC<sub>50</sub> value was determined using Origin software. The cell growth/inhibition was expressed as the percentage of cell proliferation as compared to untreated control.

## Morphological analysis

HT-29 cells were cultured in 6-well plate. After reaching 70% confluency, the cells were subjected to serum starvation for 6h. The cells were treated with various doses of the Drug **11j** (0, 5, 6.8  $\mu\text{M}$ ) for 24h. At the end of 24 hour's media was changed to fresh 10% FBS media containing Hoechst 33342 and the live cell morphology was observed under inverted microscope (Primovert, Zeiss) and the live cell images were captured using ZOE, cell imager (Bio-Rad).

## Live and dead cell assay

Briefly, HT-29 cells were cultured in 6-well plate. After reaching 70% confluency, the cells were subjected to serum starvation for 6h. The cells were treated with various doses of the Complex**11j** (0, 5, 6.8  $\mu\text{M}$ ) for 24 h. At the end of 24 h media was changed to fresh 10% FBS media with 5  $\mu\text{L}$  of 10 mM DCFDA so as to obtain a final concentration of 5  $\mu\text{M}$ ; 5 $\mu\text{L}$  of 10 mg/mL Hoechst solution (final concentration 5  $\mu\text{g}/\text{ml}$ ) and 200  $\mu\text{L}$  of 1 mg/mL propidium iodide (final concentration 20 $\mu\text{g}/\text{ml}$ ). Then the cells were incubated for 30 minutes in 37 °C incubator. After the completion of 30 minutes of incubation, the staining media was discarded and fresh media change was given before observation under fluorescent imager. The live cell nuclei was visible in blue (with Hoechst 33342 dye), the apoptotic cells were visible as pale blue with fragmented nuclei (with Hoechst 33342 dye) while the damaged cells were Red with PI. Captured images were then subjected to live and dead cell enumeration using ImageJ software and represented graphically.

## Cell cycle analysis

For cell cycle analysis, approximately 1 million HT-29 cells were treated with the drug **11j** with concentrations 5  $\mu\text{M}$  AND 6.8  $\mu\text{M}$  respectively. After 24 hours of treatment, the cells were fixed with chilled 70% ethanol for 2 hours. Fixed cells were washed with PBS and stained with 500 $\mu\text{l}$  of the FxCycle™ PI/ RNase solution (Thermo Fisher Scientific, USA) for 30 minutes in dark. The cells were analysed using Guava EasyCyte Flow Cytometer (Millipore Sigma, USA). Untreated HT-29 cells were taken as control. Serum starvation for 6 hours was given prior to the treatment. Cell cycle data was analysed by FCS express 5.0 software (by De Novo software).

## Annexin-V-FITC assay/ Apoptosis assay

Apoptosis was evaluated using PI/Annexin-V-FITC apoptosis detection kit (Invitrogen, Thermo Fisher). Briefly, cells cultured in 6 well plate were trypsinized, washed, stained with Annexin V-

FITC and PI for 15 min at room temperature in dark, and then analysed by guava easyCyte flow cytometer (Merck, Germany). This assay was repeated in 3 independent experiments and the data was analysed by FCS express 5.0 software (by De Novo software).

### **Statistical analysis**

All the experiments were carried as biological and technical triplicates and results are presented as mean  $\pm$  SD. The differences between more than two groups were analysed by two-way ANOVA. The P values of  $P \leq 0.05$  (\*\*) and  $P \leq 0.01$  (\*\*\*) were considered as significant. Error bar represents the  $\pm$  standard error of mean by using graph pad prism software.

### **Author Contributions**

**Ashaparna Mondal and Nilmadhab Roy**– Synthesis, characterization, photophysical study, DNA and BSA binding study of all the complexes

**Utsav Sen** - Biological evaluation of all synthesized compounds

**Suban Kumar Sahoo**–DFT study

**Venkatesan Muthukumar**–Stability study in UV and NMR

**Priyankar Paira and Bipasha Bose**- Manuscript preparation.

## Reference and Notes:

- 1 (a) G. R.Jadhav, S. Sinha, M. Chhabra, P. Paira, *Bioorg. Med. Chem. Lett.* 2016, **26**, 2695–2700; (b) S. K.Subran, S. Banerjee, A.Mondal, P. Paira, *New J. Chem.*, 2016, **40**, 10333—10343; (c) A.Mondal, S. De, S.Maiti, B.Sarkar, A.K.Sk, R. Jacob, A. Moorthy, P. Paira, *Journal of Photochemistry & Photobiology, B: Biology*, 2018, **178**, 380–394; (d) S. De, S. Ray Chaudhuri, A. Panda, G. R. Jadhav, R. S. Kumar, P. Manohar, N. Ramesh, A. Mondal, A.Moorthy, S. Banerjee, P. Paira, A. K.SK,*New J. Chem.*, 2019, **43**, 3291-3302; (e) B. Sarkar, A.Mondal, Y.Madaan, N.Roy, A. Moorthy, Y. –C.Kuo, P. Paira, *Dalton Transaction*, 2019, **48**, 12257-12271.
- 2 R. Menicagli, S. Samaritani, G. Signore, F. Vaglini, L. Dalla, *J. Med. Chem.* 2004, **47**, 4649–4652.
- 3 a) W. J. Geary, *Coord. Chem. Rev.*, 1971, **7**, 81–122; (b) I. Ali, W. A. Wani, K. Saleem, *Synth. React. Inorg. Met. Org. Chem*, 2013, **43**, 1162–1170.
- 4 M. R. Gill, J. A. Thomas, *Chem. Soc. Rev.* 2012, **41**, 3179-3192.
- 5 M. Sirajuddin, S. Ali, A. Badshah, *J. Photochem. Photobio. B: Bio.*, 2013, **124**, 1–19.
- 6 M. S. Sani, F. Shirini, M. Abedini, M. Seddighi, *Res. Chem. Intermed.*, 2016, **42**, 1091–1099.
- 7 S. Dasari, A. K. Patra, *Dalton Trans.* 2015, **44**, 19844-19855.
- 8 J. Keizer, *J. Am. Chem. Soc.*, 1983, **105**, 1494–1498.
- 9 V. D. Suryawanshi, L. S. Walekar, A. H. Gore, P. V. Anbhule, G. B. Kolekar, *J. Pharm. Anal.* 2016, **6**, 56–63.
- 10 T.Nakamura, M.Oka, K. Aizawa, H.Soda, M. Fukuda, Terashi, K. Ikeda, Y. Mizuta, Y. Noguchi, Y.Kimura, T. Tsuruo, S. Kohno, *Biochem. Bioph. Res. Co.*, 1999, **255**, 618-624.
- 11J. Liu, J. Tian, W. He, J. Xie, Z. Hu, X. Chen, *J. Pharm. Biomed. Anal.*, 2004, **35**, 671-677.
- 12H. Tanak, *J. Mol. Struc.* 2015, **1090**, 86-92.

